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Abstract 
Post-thaw washing of cryopreserved blood stem cells is intended to reduce 
side effects and is an increasingly common practice in A utologous Stem Cell 
Transplantation ( ASCT). However, the potential advantages of this extra ma-
nipulation have not been fully evaluated, and needs to be balanced against 
the fact that patient morbidity has already been significantly lowered by 
reductions in the reinfusion volume (achieved through refined harvesting, 
mobilising and processing techniques) and improved patient pre-medication. 
This study modified and validated the New York Cord Blood Banks wash-
ing protocol (Rubinstein et al. 1995). Parameters validated included; cell 
loss, overall viability, viable CD34+stem cell enumeration, clonogenic poten-
tial and reduction in free haemoglobin content. The results demonstrate that 
washing of cryopreserved stem cells improves the outcome of several key labo-
ratory parameters without a significant negative impact upon haematopoietic 
stem cell (HSC) engraftment potential. 
To determine whether a clinical need exists for the routine washing of 
cryopreserved HSC autografts, a single institution, non-randomised clinical 
trial was performed. Patients who met trial eligibility criteria were consented 
for the washing of their ASCT graft, whereas all other transplant patients 
received thawed unwashed blood stem cells in accordance with current prac-
tice. Reinfusion associated side effects experienced by patients, their close 
family members (carers) and nurses following the infusion of washed or un-
washed stem cells were assessed using both a Quality of Life (QOL) survey 
and nursing documentation forms. The surveys were self-completed by the 
patient, the nurse and the carer at intervals over a 24 hour period. Statisti-
cal analysis of the QOL data demonstrated that washing was associated with 
an improvement in several side effects associated with reinfusion including 
flushing, nausea and unpleasant tastes for patients and unusual smells for 
both carers and nurses. Furthermore, the clinical observations indicate that 
the washing protocol reduces transplant associated hypertension in ASCT 
patients and is an improvement on the reinfusion of unwashed HSC, which 
has a significant correlation with increased blood pressure. 
viii 
Consequently, this study has identified a number of circumstances in 
which a post-thawing washing of HSC autografts is potentially beneficial 
for the patients. The washing protocol reduces the amount of cellular debris 
and DMSO reinfused as well as diminishing patient discomfort and therefore 
should be considered in the event of large volume reinfusions, patient allergies 
or where hemodilution may exacerbate existing cardiac issues. Furthermore, 
post-thaw washing of HSC should also be contemplated in the event of un-
expected delays between autograft thawing and reinfusion as a strategy for 
extending the viability of HSC. 
Foreword 
Autologous stem cell transplantation (ASCT) after high dose chemotherapy 
is increasingly being used as a treatment for acute leukaemia, lymphoma 
and solid tumours and requires the cryopreservation and storage of autol-
ogous stem cells harvested from bone marrow or peripheral blood during 
remission. The stem cells are frozen in liquid nitrogen and subsequently 
stored at ultra-low temperatures until required for a transplant, sometimes 
years later. In order to prevent damage to the stem cells by ice crystals 
a cryoprotectant, dimethyl sulfoxide (DMSO) is added to the cells prior to 
freezing and is subsequently reinfused into the patients along with the cellular 
contents. A number of DMSO-related toxicities has been reported includ-
ing headache, nausea, abdominal cramping, flushing, decreased heart rate, 
neurological toxicity and increased blood pressure. Similarly, red blood cells 
are destroyed during the freezing process, and the reinfusion of red cell lysis 
products exert additional toxic effects to the patient. 
Whilst the toxic side effects of DMSO infusion are well known, there has 
been significant concern that removing this compound prior to transplant 
will reduce stem cell viability and numbers and hence increase the risk of 
graft failure. 
This study was undertaken to validate a method of removing DMSO and 
cellular lysis products from thawed autologous stem cell collections without 
comprising the engraftment potential and to assess the impact on patient 
well-being using a quality of life survey. 
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Chapter 1 
Literature Review 
1.1 Haematopoietic Stem Cell Transplanta-
tion 
Autologous stem cell transplantation (ASCT) is an established clinical prac-
tice, frequently used in the treatment of lymphomas, leukaemias and solid 
tumours. It involves the intravenous reinfusion of the patients haematopoi-
etic stem cells (HSC), obtained from bone marrow (BM) or peripheral blood 
(PB) following high dose chemotherapy. These stem cells are harvested from 
the patient preceding the transplant and are stored at 196C in liquid ni-
trogen until required. Prior to freezing, the stem cells are treated with a 
chemical called dimethyl sulphoxide (DMSO), which prevents cell death dur-
ing the freezing and thawing process. At the actual transplant, the patient 
is reinfused with the entire contents of the thawed harvest; that is, stem 
cells, DMSO, and blood cell breakdown products. This review considers the 
toxicity of the reinfused products and its effects on patient well being. 
1.1.1 Historical Perspective 
The first recorded use of BM to treat disease occurred in 1891 (Brown-
Sequard and d'Arsonaval) with the oral administration of glycerol extracts of 
BM to anaemic patients suffering from leukaemia (reviewed by [Johnson, 1981]). 
Attempts at finding the best method of administering cells continued into the 
early 20th century with the use of intramuscular injections of freshly prepared 
BM (Schretzenmayr 1937) as an unsuccessful treatment of anaemia related to 
malaria (reviewed by [Santos, 1983]). In 1944, following 5 years of investiga-
tion Jean Bernard reported that injections of small volumes of BM (2.0-6.0 
ml) directly into the medullary cavity were ineffective for cellular transplan-
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tation (reviewed by [Johnson, 1981]). The first report of intravenous admin-
istration of BM [Osgood et al., 1939] was for the unsuccessful treatment of 
aplastic anaemia using 13mls of BM collected from a sibling. It wasn't until 
the mid 1940s however that intravenous BM administration was accepted, as 
the most efficient and effective means of transplantation [Santos, 1983]. 
Post world war two investigations into the effect of irradiation resulted 
in the discovery [Jacobson et al., 1951] that erythrocyte production could 
be restored in mice, following the destruction of BM by lethal dose ra-
diation, if haematopoietic tissue, such as the spleen were shielded from 
the radiation. In addition further studies showed that the haematopoi-
etic function was restored in lethally irradiated mice and guinea pigs 
by intravenous or intra-peritoneal injections of allogeneic or syngeneic 
BM [Lorenz et al., 1951] contributing to the advancement of this field. Sub-
sequent studies [Lindsley et al., 1955, Nowell et al., 1956] showed that the 
colonisation of the recipient BM was due to the transplanted cells rather 
than to a humoral effect. 
1.1.2 Types of Transplants 
Autologous 
Autologous transplantation involves the intravenous infusion of the pa-
tients own HSCs, collected from BM or PB, to replace diseased BM or 
to replenish terminally damaged BM after the use of myeloablative ther-
apy [Armitage, 1994]. The observation that the administration of the pa-
tients' own BM (stored prior to irradiation) or BM from an identical twin 
resulted in the restoration of the patients' marrow, suggested the possi-
bility that autologous BM could be stored in anticipation of radiotherapy, 
chemotherapy or the possibility of radiation accident [Thomas et al., 1957]. 
The development of cryopreservation techniques [Mannick et al., 1960, 
Cavins et al., 1962, Buckner et al., 1970, Malinin et al., 1970] for the stor-
age of HSC at ultra low temperatures ensured the acceptance of autologous 
BM transplantation (AutoBMT) as a therapeutic practice for the treatment 
of lymphoma in the 1970s [Armitage, 1994]. 
From the 1980s onwards, ABMT has been increasingly used in the 
treatment of a variety of diseases including; acute myeloid leukaemia 
(AML), lymphoproliferative disorders, multiple myeloma (MM) and solid 
tumours. These will be discussed in further detail in section 1.2 of this re-
view [Apperley et al., 2000, Thomas, 2000]. Generally the upper age limit 
for autologous transplantation is 65 years although the patients health 
and disease status are also important considerations [Apperley et al., 2000]. 
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As Graft Versus Host Disease (GVHD) is not a complication, trans-
plant mortality for autologous transplantations is generally negligible, al-
though this procedure has its own risks, which will be outlined in sec-
tion 1.3 [Nivison-Smith et al., 2005]. 
Allogeneic 
Allogeneic transplantation involves the transfer of HSCs, collected from the 
BM or PB, of an HLA-matched related or unrelated donor, into another 
person [Armitage, 1994]. Umbilical cord blood (UCB) is also a potential 
source of allogeneic HSC [Kurtzberg et al., 1996]. 
In comparison to BM or PBSC, USB transplants (UCBT) have several 
advantages including a lower risk of severe graft versus host disease, rapid 
availability (from cord banks), lack of risk for donor and lower risk of in-
fectious diseases [Barker et al., 2005] [Brunstein and Wagner, 2006]. How-
ever the disadvantages of UCBT include the inability to "recollect" from 
a donor in the event of disease progression or relapse, lack of substantial 
experience with UCBT in comparison with the transplantation of HSCs 
derived from BM or PB and most significantly the limitation of cell dose 
which has resulted in UCB generally been restricted to the treatment of 
children [Brunstein and Wagner, 2006]. Nonetheless, in the future the use 
of UCB may be routinely expanded to adult patients as transplantation 
of two ("double") partially HLA-matched UCBs may overcome the re-
strictions of cord blood cell dose [Barker et al., 2005]. However as phase 
II clinical trials of "double" adult UCB transplants are ongoing, more 
data needs be collected and analysed before this form of HSC allogeneic 
transplant may be adopted as standard practice worldwide for adult pa-
tients [Brunstein and Wagner, 2006]. 
Early attempts at allogeneic transplantation were followed by a severe and 
rapidly fatal reaction characterised by rashes, diarrhoea and pneumonitis, 
which proved to be a major obstacle in the development of this form of trans-
plantation [Storb et al., 1970, Thomas et al., 1975, Santos, 1983]. GVHD, 
occurs when allogeneic BM recognises the tissues of the recipient as for-
eign [Janeway et al., 1999]. 
The identification of the major histocompatibility complex (MHC) HLA 
system and the subsequent ability to type and match class I and II anti-
gens for donors and recipients has contributed to a reduction in graft versus 
host disease [Apperley et al., 2000, Kollman et al., 2001]. In addition, the 
adoption of immunosuppressive agents such as 
• methotrexate [Storb et al., 1970], 
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• cyclophosphamide [Thomas et al., 1975] and 
• cyclosporine A [Ruutu et al., 2000] 
has resulted in the improved management of GVHD and improved allogeneic 
transplant outcome [Sullivan and Storb, 1984]. 
Allogeneic transplants may be considered for the treatment of a 
number of diseases including: acute and chronic leukaemias, malig-
nant lymphomas, MM, myelodysplastic syndromes (MDS) and severe 
aplastic anaemia (SAA) [Sullivan and Storb, 1984, Apperley et al., 2000, 
Nivison-Smith et al., 2005]. A major consideration in the decision for al-
logeneic transplantation is the age of the recipient, as there is a increased 
frequency of GVHD with age [Armitage, 1994]. As a general rule 60 years 
is the age limit for the use of HLA-identical sibling donors and 45 years the 
age limit for unrelated donor transplants [Apperley et al., 2000]. 
The availability of compatible donors as well as the individual patient's 
health and disease status are also major considerations in the decision to 
perform allogeneic transplant [McGlave, 1985, Nivison-Smith et al., 2005]. 
This form of HSC transplantation initially has higher transplant related 
mortality and initial worse survival and disease free survival in compari-
son to autologous procedures. On the other hand, unlike autologous trans-
plants allogeneic transplants are potentially curative [Armitage, 1994]. To-
day the number of autologous transplant procedures performed exceeds 
allogeneic procedures as increasing applications are found for this proce-
dure [Apperley et al., 2000, Nivison-Smith et al., 2005]. 
1.1.3 Sources of Autologous Transplant Material 
Bone Marrow 
As the site of HSC production, BM was the original source of HSCs 
and it remains an acceptable source today. Harvesting BM to ob-
tain HSCs involves multiple aspirations from the iliac posterior crests, 
in an operating theatre, under sterile conditions and general anaesthe-
sia [Thomas and Storb, 1970] until sufficient mononuclear cells have been 
removed, ideally 3 x 108 /kg [Apperley et al., 2000]. The development of 
recombinant cytokines such as granulocyte colony-stimulating factor ( G-
CSF) [To et al., 1998] resulted in mobilisation of HSCs, increasing BM har-
vest yields including those of patients who had received previous cytotoxic 
chemotherapy [Tegg et al., 1999]. 
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Peripheral Blood 
The presence of HSC in blood was recognised in animals and humans in the 
1960s [Goodman and Hodgson, 1962, McCreddie et al., 1971] however it was 
not until the 1980s that PB HSC harvests were performed on humans. Ini-
tially there were difficulties obtaining sufficient cells for transplantation by 
aphaeresis, as levels of HSCs in PB were approximately 100 times less than 
in BM [Gillespie and Hillyer, 1996]. HSC yields were significantly improved, 
however, by timing PB collections to coincide with white cell count (WCC) 
increases, post recovery from myelosuppressive chemotherapy [To et al., 1984, 
Juttner et al., 1985, To et al., 1990, To et al., 1997]. Furthermore, the use 
of haematopoetic growth factors such as G-CSF and stem cell factor (SCF) 
to mobilise HSCs [Molineux et al., 1990] also resulted in dramatic increases 
in HSC numbers [de Revel et al., 1994]. Today PB collections are generally 
primed with G-CSF and/ or chemotherapy to ensure adequate HSC collection 
numbers [Apperley et al., 2000]. 
The reduced transfusion requirements and hospital admissions for pa-
tients receiving HSC obtained from PB, as a result of faster recovery of neu-
trophils and platelets [Champlin et al., 2000, Vellenga et al., 2001] are some 
of the reasons that PB harvests are the preferred source of HSC [Gillespie and Hillyer, 1996, 
Nivison-Smith et al., 2005]. In addition, PB harvest~ are performed as out-
patient procedures and the daily monitoring of CD34+(a haematopoietic stem 
cell marker) numbers in the PB pre harvest can provide a reliable guide to 
HSC mobilisation prior to collection to ensure that harvests are performed 
when HSC rebound [Hass et al., 1994]. 
1. 2 Indications 
ASCT is increasingly considered as a treatment option for an expanding range 
of diseases including lymphomas, leukaemias, solid tumours and multiple 
myeloma. 
1.2.1 Non-Hodgkins Lymphoma 
Successful treatment of NHL with intensive chemotherapy and autologous 
HSC began in the 1970s [Appelbaum et al., 1978, Santos, 1983] and remains 
a treatment option for patients with chemotherapy-sensitive relapse of high or 
intermediate grade NHL and lymphoblastic lymphoma [Schmitz et al., 1996, 
Apperley et al., 2000, Vose et al., 2001]. A comparison study of ABMT with 
salvage chemotherapy, of 215 patients with relapses of NHL (intermedi-
ate and high grade) [Philip et al., 1995] reported event free survival at 5 
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years of 46% for recipients versus 12% for patients receiving chemother-
apy alone (P=0.001) and an overall survival rate of 53% and 32% re-
spectively (P=0.038). While ASCT survival data suggests a benefit for 
these patients in comparison to standard chemotherapy alone, the risks in-
crease with patients over 60 years old [Chen et al., 2001]. Nevertheless, the 
ABMTRR reports that at eleven years post transplant, ASCT patients have 
a 39% survival probability compared with 37% for allogeneic related recipi-
ents [Nivison-Smith et al., 2005]. 
The effectiveness of the treatment of low grade NHL by ASCT re-
mains uncertain [Apperley et al., 2000] as allogeneic transplants may offer 
a better chance of a cure as a graft versus low grade lymphoma effect 
may exist. A comparison study of 28 patients with refractory and recur-
rent low-grade NHL treated with allogeneic versus autologous transplanta-
tion [Verdonck et al., 1997] reported event-free survival rates at two years of 
68% for allogeneic BMT patients and 22% for autologous BMT recipients. 
1.2.2 Multiple Myeloma 
ASCT for MM patients began in the late 1980s, following the observation 
that the myelotoxicity of high-dose melphalan, which has been standard 
treatment for MM for over thirty years, was reduced in patients following 
ABMT [Barlogie et al., 1986, Samson and Singer, 2001, Barlogie et al., 2004] 
Several comparison studies of ASCT and chemotherapy for treatment of MM 
have all reported improved event-free survival and overall survival of patients 
of approximately 52% at 5 years [Barlogie et al., 1997, Desikan et al., 2000, 
Lenhoff et al., 2000, Blade et al., 2003]. However, the presence of chromo-
some 13 abnormalities in some MM patients has been recognised as a poor 
prognostic feature [Jacobson et al., 2003] for ASCT outcome, with one report 
of 5 year event-free survival of 0% and overall to 16% [Desikan et al., 2000]. 
The ABMTRR reports that eleven years post transplant ASCT patients have 
a 25 % survival probability compared with 24% for allogeneic related recipi-
ents [Nivison-Smith et al., 2005]. 
1.2.3 Acute Myeloid Leukaemia 
For AML patients over 45 years of age without an HLA matched donor, 
ASCT with intensive chemotherapy in first remission remains a treatment 
option [Champlin and Gale, 1987, Apperley et al., 2000]. As GVHD is not 
an issue, transplant morbidity and mortality for AML patients receiving 
autologous HSC transplants is reduced in comparison to allograft transplants, 
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however disease relapse remains a major cause of patient death following 
autologous transplantation [Burnett et al., 1998]. 
Comparison studies of allogeneic transplants and autologous trans-
plants with intensive chemotherapy report average disease-free survivals 
ranging from 48% to 553 at three to seven years [McMillan et al., 1990, 
Zittoun et al., 1995, Burnett et al., 1998, Tsimberidou et al., 2003]. In ad-
dition, all these studies concluded that ASCT results in improved disease 
free survival in comparison to intensive chemotherapy. Furthermore, the 
Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) re-
ports that at eleven years post transplant, good prognosis ASCT patients 
have a 47% survival probability [Nivison-Smith et al., 2005]. 
1.2.4 Solid Tumours 
ASCT also continues to be used in the treatment of solid tumours to replenish 
bone marrow which has been terminally damaged by high-dose chemother-
apy used to destroy diseases such as neuroblastomas, glioma, soft-tissue 
sarcomas, germ cell tumours and Ewing's sarcoma [Apperley et al., 2000, 
Nivison-Smith et al., 2005, Gratwohl et al., 2004]. 
A 10 year European Blood and Marrow Transplantation (EBMT) study 
of 27902 HSCT reports a decline in use of ASCT for breast cancer, small cell 
lung cancer and ovarian cancers following an initial increase in transplant 
numbers up to 1997 [Gratwohl et al., 2004]. In the 1990s the most common 
solid tumour treated by ASCT was breast cancer, following the presenta-
tion of data at a meeting of the American Society of Clinical Oncology of a 
randomised trial of 154 patients [Bezwoda, 1999] demonstrating significant 
survival following high dose chemotherapy and ASCT. However a review of 
this study by a team of American investigators found serious inaccuracies 
and breaches of acceptable research practice in the study (Bearman, 2000; 
Ford, 2001). As a result, the findings have been revoked and ASCT is no 
longer promoted, as a treatment option for breast cancer patients as it does 
not appear to improve patient survival. 
1.2.5 Other Diseases 
ASCT may also be less commonly considered in the treatment of 
a number of diseases, including Chronic Myeloid Leukaemia ( CML), 
Hodgkin's disease (HD), Amyloid light chain (AL) depending on pa-
tient age, disease status and availability of HLA-matched allogeneic 
donors [Apperley et al., 2000] [Gertz et al., 2004]. 
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CML was the first disease for which ASCT was performed using HSCs 
collected by aphaeresis as large numbers of nucleated cells are present 
in the PB [Goldman et al., 1978]. In an attempt to retard the progress 
of the disease, albeit temporarily by restoring the chronic phase, ASCT 
may be of benefit for CML patients as HSCs collected while the pa-
tient is in chronic phase are transplanted when the patient progresses 
to blastic phase [Lemonnier et al., 1986, Cheson et al., 1989]. However 
as the transplanted cells are Ph+, the disease can not be cured by 
ASCT [Champlin and Gale, 1987]. ABMTRR reports that eleven years post 
transplant ASCT good risk patients have a 56% survival probability com-
pared with 14% for poor risk ASCT patients [Nivison-Smith et al., 2005]. 
ASCT is considered as a treatment option for patient's with HD treated 
initially with chemotherapy who relapse, as well as HD patients with ad-
vanced HD treated with chemotherapy who do not enter complete remis-
sion [Apperley et al., 2000]. A three year comparison study of PB versus 
BM ASCT for 70 matched pairs of patients with HD treated with BEAM 
reported a overall survival of 68.6% for BMT and 78.2% for PBSCT and no 
major overall or progression-free survival advantage for PBSCT compared to 
ABMT [Perry et al., 1999]. A long-term follow-up study of 55 patients with 
relapsed or refractory HD treated with ASCT following Mini-Beam BCNU 
( carmustine, etoposide, cytarabine, melphalan) chemotherapy reported the 
overall seven year survival was 52%, the progression-free survival 543 and the 
event-free survival 363 [Martin et al., 2001]. Furthermore, the ABMTRR 
reports that at eleven years post transplant, ASCT HD patients (n = 420) 
have a 603 survival probability compared with 0 3 for allogeneic related 
recipients (n = 12) [Nivison-Smith et al., 2005]. 
AL is a disorder of plasma cells resulting in the synthesis and deposition 
of insoluble immunoglobulin light chains in various organ systems causing 
progessive organ failure and death with a median survival of one year with-
out ASCT [Benekli et al., 2000] [Worel et al., 2006]. Patient age, number of 
organs involved and extent of cardiac involvement are all strong indicators of 
patient survival following ASCT [Gertz et al., 2004]. However, AL patients 
generally report higher rates of morbidity and mortality following ASCT than 
other ASCT patients [Gertz et al., 2004] [Worel et al., 2006]. Nevertheless, 
ASCT can induce response rates of approximately 603,with a recent study 
reporting 673 of patients ( 4/6) alive after a median follow-up of 39 months 
post ASCT [Worel et al., 2006]. 
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1.3 Risks/Morbidity/Mortality of Autologous 
Transplantation 
1. 3.1 Recurrent Disease 
While ASCT avoids the risks of GVHD associated with allogeneic trans-
plants there remains the risk that the harvest will contain diseased 
cells [Champlin and Gale, 1987] and relapse is more common following au-
tologous transplantation than allogeneic transplantation [Armitage, 1994, 
Schimmer et al., 2000]. Disease relapse was the cause of 52.73 of deaths in 
the first year after transplant for autologous transplants performed in Aus-
tralia between 1991 and 2002. This figure rose to 79.6% as the cause of death 
in the second year post transplant [Nivison-Smith et al., 2005]. In addition, 
the graft versus leukaemia effect present in allogeneic transplants, associated 
with reduced relapse rates [Horowitz et al., 1990], is absent in autologous 
transplants, which may contribute to increased rates of relapse post trans-
plantation when compared to allogeneic transplants [Zittoun et al., 1995]. 
With improved patient survival post ASCT, a small but signifi-
cant risk of secondary cancers has been reported in patients treated 
for NHL and HD following use of chemotherapy and radiotherapy sup-
ported by ASCT [Witherspoon et al., 1989]. Post transplant therapy re-
lated myelodysplasia (t-MDS) and secondary therapy-related acute myeloid 
leukaemia (t-AML) have been reported as long term complications of 
ASCT [Mach-Pascual et al., 1998]. Prior chemotherapy with large doses 
of alkylating agents has been suggested as an important risk factor as 
have older age at time of diagnosis and transplant as well as exposure 
to previous radiotherapy, especially total body irradiation (TBI) prior to 
ASCT [Pedersen-Bjergaard et al., 2000, Metayer et al., 2003]. 
A retrospective study of 612 patients who had received ASCT for HD 
and NHL reported 22 cases of t-MDS/t-AML at a median of 1.9 years 
from transplant, with a 12.3 fold increased risk of developing t-AML with 
llq23/21q22 abnormalities in patients who received VP-16 for RSC mobilisa-
tion [Krishnan et al., 2000]. Another study of 104 female patients receiving 
ASCT for NHL evaluated the predictive value of clonal BM haematopoiesis 
for the development of t-MDS/ AML using an X-inactivation based clonal-
ity assay at the human androgen receptor locus (HUMARA). They con-
cluded that a significant proportion of patients have clonal haematopoiesis 
at the time of ABMT and that clonal haematopoiesis, as detected by 
the HUMARA assay was predictive of the development of t-MDS/ AML 
(P=0.004) [Mach-Pascual et al., 1998]. 
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1.3.2 Neutropenia 
One of the major indicators of successful HSC engraftment is the 
time taken for neutrophil numbers to recover to 0.5 and 1.0 x 
-109 I L [Nivison-Smith et al., 2005]. During this time the patient is neu-
tropenic and hence vulnerable to infections [Hoffman and Pettit, 1989]. The 
use of G-CSF post ASCT to promote HSC production has reduced the 
neutropenic phase post transplantation. In addition, the increasingly pre-
ferred use of PB HSC, and the associated improved recovery time for neu-
trophils [Damiani et al., 1997] continues to reduce the neutropenic phase and 
hospital stays [Vellenga et al., 2001, Nivison-Smith et al., 2005]. 
1.3.3 Sepsis 
Although ASCT recipients are not affected by GVHD post transplant infec-
tions, they remain vulnerable to infection, especially during the neutropenic 
phase. Septicaemia accounts for 3.93 of deaths in the first year post ASCT 
in Australasia [Nivison-Smith et al., 2005] arid as the majority of patients 
experience sepsis post transplantation, all ASCT patients are closely mon-
itored. Most ASCT patients however, require hospitalisation for bacterial 
and fungal infections, which can be treated with broad-spectrum antibiotics 
and anti fungal agents [Willams et al., 1990]. 
1.3.4 Thrombocytopenia 
The number of days taken for platelet numbers to reach 20 and 50 x 109 /L 
are also used as indicators of the HSC engraftment [To et al., 1998]. Throm-
bocytopenia with bleeding, is a serious, although uncommon complica-
tion of ASCT and occurs mostly in patients refractory to platelet trans-
fusions [Willams et al., 1990]. As with neutrophil recovery the use of G-
CSF post transplant to promote maturation of HSC and the increasing 
use of PB as a source of HSC has reduced periods of thrombocytope-
nia [Champlin et al., 2000, Vellenga et al., 2001] and hence transfusion re-
quirements. 
1.3.5 Reinfusion Risks 
The intravenous reinfusion of cryopreserved HSC has been associated 
with numerous side effects including: renal failure, nausea, vomiting, 
headaches, cardiac and neurological complications [Stroncek et al., 1991, 
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Styler et al., 1992, Okamoto et al., 1993, Limaye, 1997]. The causes and 
symptoms of reinfusion toxicity will be discussed in detail in section 1.6. 
1.4 Stem Cell Processing and Assessment of 
Engraftment Potential 
1.4.1 Bone Marrow Processing (Volume and RBC re-
duction) 
As described in section 1.1.3, unprimed BM or BM primed by G-CSF is col-
lected from the iliac crests, of patients under general anaesthetic by multiple 
aspirations, to which anticoagulant such as Acid Citrate Dextrose Antico-
agulant (ACDA) or Heparin is added in controlled ratios to prevent clot-
ting [To et al., 1998]. The BM harvest must also be filtered to remove fat, 
bone fragments and aggregates, either during collection or subsequent pro-
cessing [Apperley et al., 2000]. The volume of cells removed from patients is 
determined by both the patient's weight and the nucleated cell count (NCC) 
per kg, which is calculated from the mid harvest full blood count. The rec-
ommendation of 3 x 108 NCC/kg is used to provide an indication of the 
adequacy of the harvest by using the number of nucleated cells as a guide 
to HSC numbers [Apperley et al., 2000]. This will be discussed in detail in 
section 1.4.2. 
Following the completion of the aspirations, the BM harvest must be 
further processed by the use of centrifugation, to separate the cellular and 
plasma components. Generally a closed system, such as a cell washer or an 
aphaeresis cell separator, is used for this purpose in preference to a open 
system such as ficoll density separation [To et al., 1998]. The aim of this 
procedure is two fold; firstly to reduce the product volume by the removal 
of excess plasma and red cells, and secondly to isolate the huffy coat which 
contains concentrated mononuclear and hence HSCs, which is then ready for 
cryopreservation [Wells et al., 1979, To et al., 1998]. 
1.4.2 Peripheral Blood Processing 
Collections of HSC from PB follow priming by G-CSF with/without chemother-
apy, commence when the WCC rises post nadir to 1.0 x 109 /L, at which point 
most institutions begin CD34 testing. When CD34+HSC numbers reach the 
institution's prescribed starting point (5-10 x 106 /ml), collection of HSC us-
ing mononuclear aphaeresis begins [Boiron et al., 1996]. PB collections are 
performed using continuous-flow cell separators to process, on average, 10 
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litres of blood but this is dependent on the patients needs [Apperley et al., 2000]. 
As red blood cells and plasma are returned to the patient throughout the 
process, the ultimate product of the aphaeresis is a huffy coat containing 
mononuclear cells suspended in plasma, which is then ready for cryopreser-
vation. 
1.4.3 Cryopreservation 
Cryopreservation of HSCs evolved from animal [Mannick et al., 1960, 
Thomas and Ferrebee, 1962, Cavins et al., 1962, Buckner et al., 1970] and 
human studies [Malinin et al., 1970, Rybka et al., 1980] as a result of the 
need for long-term maintenance of HSC viability and function until the ASCT 
was performed. Cryoprotectant agents and the effect of storage on HSC func-
tion will be discussed in detail in section 1.5. 
Following the addition of the cryoprotectant solution to HSCs, the sus-
pensions are then cryopreserved in a controlled rate freezer with a cooling 
rate of 1°C-3°C per min to at least -40 °C. Upon completion of the freez-
ing run the HSC are transferred to long term storage using liquid or vapour 
phase nitrogen at a temperature below -120 °C [To et al., 1998]. 
1.4.4 Assessment of Engraftment Potential 
As HSC can not be identified by cell morphology, other methods have evolved 
to assess the engraftment potential of HSC harvests [Audet et al., 1998]. The 
earliest method of assessing engraftment potential was simply to monitor 
the recovery of haematological function of lethally irradiated subjects (both 
animal and human) post ASCT [Buckner et al., 1970, Malinin et al., 1970] 
and it still remains the ultimate test [Rybka et al., 1980]. 
The NCC per kg of patient weight of HSC harvests (i.e. cell dose) has been 
used as a indicator of neutrophil and platelet recovery [Stewart et al., 1989]. 
However, as NCC includes various nucleated cells including mature neu-
trophils, which do not survive freezing and thawing [Rybka et al., 1980], 
the validity of NCC as a indicator of engraftment potential has been ques-
tioned [al Fiar et al., 1997]. These findings are supported by an earlier study 
which also concluded that the dose of mononuclear cells infused did not cor-
relate with neutrophil and platelet recovery [van der Wall et al., 1994]. Fur-
thermore, Rowley et al 1994 reported that the cellular concentration of the 
cryopreserved cells (Le.cells per ml) prior to freezing is also not predictive 
of post-thaw recovery of nucleated cells (P=0.38), granulocyte-macrophage 
colony-forming unit (GM-CFU)(P=0.06) or CD34+cells (P=0.54), or for the 
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viability of mononuclear cells (P=0.81). Additionally, the cellular concentra-
tion of the cryopreserved product did not predict the time of neutrophil and 
platelet recovery post ASCT [Rowley et al., 1994]. 
The need for a in vitro assay to assess HSC collections was clearly 
identified and so progenitor cell assays for neutrophils, macrophages and 
erythrocytes evolved [Appelbaum et al., 1978, Apperley et al., 2000]. The 
Colony Forming Units Granulocyte Macrophage (CFU-GM) assay is rou-
tinely performed to assess the ability of the HSCs to engraft and ma-
ture into macrophages and granulocytes, an indication of the haematopoi-
etic progenitor content of a stem cell collection [Eaves and Lambie, 1995]. 
CFU-GM assays do not provide information on primitive progeni-
tors or progenitor cells committed to other lineages and are conse-
quently an indirect test of engraftment potential [Appelbaum et al., 1978, 
Rybka et al., 1980, To et al., 1997]. Correlation of neutrophil and platelet 
recovery with CFU-GM numbers has been demonstrated by numer-
ous studies [Spitzer et al., 1980, Rybka et al., 1980, Lemonnier et al., 1986, 
Rowley et al., 1994, van der Wall et al., 1994]. 
Although the CFU-GM assay provides valuable information regarding 
the proliferative potential of HSC collections it has several limitations. The 
14 day incubation period required for CFU-GM assays ensures that this 
method can not be used for rapid assessment of HSC numbers prior to PB 
collection [Hass et al., 1994]. In addition, CFU-GM assays have exhibited 
poor reproducibility of results and therefore are being increasingly replaced 
by CD34+analysis [Chang and Ma, 1998, Rock et al., 2000]. 
The enumeration of cells expressing CD34 +antigens is the gold 
standard for assessment of stem cell collections engraftment potential, 
as it provides a rapid indication of HSC numbers [Siena et al., 1991, 
Keeney et al., 1998]. As CD34 analysis can be performed in approx-
imately 1 hour, it is the most suitable method of monitoring HSCs 
during PB mobilisation, to allow optimisation of aphaeresis collec-
tions [Hass et al., 1994, Keeney et al., 1998]. Correlation of CD34 numbers 
with platelet and neutrophil recovery has been demonstrated by numerous 
studies [Rowley et al., 1994, van der Wall et al., 1994, Keeney et al., 1998, 
Apperley et al., 2000]. CD34+assay results of HSC may not always corre-
late with CFU-GM assay results as the CD34 antigen is found on both HSC 
and committed progenitors, with only a portion of the CD34+cells capa-
ble of triggering and sustaining long-term haematopoiesis. The CD34 anti-
gen is believed to be involved in cell-cell interactions or cell-matrix adhe-
sions [Chang and Ma, 1998]. 
The adoption of International Society of Hematotherapy and Graft En-
gineering (ISHAGE) guidelines for detection of CD34+cells based on a 
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four parameter flow cytometry method (CD45FITC/CD34 PE staining, 
side and forward angle light scatter) [Keeney et al., 1998] by most insti-
tutions should increasingly counter the lack of inter-institutional repro-
ducibility [Chang and Ma, 1998, Rock et al., 2000]. The modification of the 
ISHAGE guidelines by the addition of a known number of fluorescent mi-
crospheres, removes the need for a wee from a automated haematology 
analyser consequently removing another source of potential error, while con-
verting the flow cytometer into a single platform CD34+cell-counting de-
vice [Keeney et al., 1998]. The incorporation of viability dyes such as 7 AAD 
into single platform analysis allows the determination of the absolute viable 
CD34+cell count which can then be used for post cryopreservation sample 
analysis [Keeney et al., 1998]. 
Currently 1.5-2.0 x 105 CFU-GM/kg or 1-2 x 106 CD34+cells/kg are 
generally agreed as the minimum threshold below which haematopoietic re-
constitution will not occur [To et al., 1997]. 
1.5 Cryobiology 
1.5.1 Cryoprotective Agents 
Cryopreservation of HSC requires the addition of a cryoprotectant to 
preserve cell viability and function during storage at ultra low tem-
peratures for variable lengths of time [Apperley et al., 2000]. With-
out a suitable cryoprotectant the formation of intra-cellular ice may 
rupture HSCs and extra-cellular ice formation will result in the de-
hydration of HSCs as water is taken up by the growing ice crys-
tals [Rowley and Anderson, 1993]. Cryoprotectants including glycerol, hy-
droxylethyl starch (HES) and dimethyl sulfoxide (DMSO) have all been used 
in the cryopreservation of HSC [Rowley and Anderson, 1993]. 
Although there are small variations in technique between institutions 
currently the majority of institutions use a mixture of 5-15% DMSO and 
1-25%(v/v) protein supplement (autologous plasma or human serum albu-
min), which is added to the HSC so that nucleated cell concentration (NCC) 
remains below 3 x 108 /ml [To et al., 1998, Apperley et al., 2000]. Samples 
of HSC suspension are removed for microbial contamination testing prior to 
cryopreservation [To et al., 1998]. 
DMSO, a by product of the paper industry, is the principal cry-
oprotectant used in the cryopreservation of haematopoietic stem cells 
(HSC) intended for autologous transplantation after high dose chemother-
apy [Rowley et al., 1999a]. DMSO, a dipolar, aprotic solvent acts as a pen-
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etrating agent, protecting HSC from ice crystallisation on a molecular ba-
sis by reducing the electrolyte concentration in the residual unfrozen solu-
tion [Rowley, 1992]. The hydrogen bonding between DMSO and water is ap-
proximately 1.3 times stronger than between water and water [Brayton, 1986] 
although these properties are only exhibited within a certain concentration 
range [Swanson, 1985]. The optimum concentration of DMSO appears to be 
between 5 and 103 of the final frozen volume [Apperley et al., 2000]. 
The effectiveness of 103 DMSO as a cryoprotectant in an-
imals studies [Cavins et al., 1962, Malinin et al., 1970, Swanson, 1985] 
lead to the acceptance of DMSO in the cryopreservation of human 
HSC [Buckner et al., 1970]. However, DMSO poorly preserves granulocytes 
and erythrocytes as the osmotic tolerance of these cells is much less than lym-
phocytes and HSC [Brayton, 1986, Davis et al., 1990, Rowley, 1992]. Con-
sequently, the reinfusion of cryopreserved HSCs has been associated with 
DMSO related toxicities, which will be discussed in greater detail in sec-
tion 1.6 [Rowley and Anderson, 1993]. 
1.5.2 Effect of Storage on HSC Function (Tempera-
ture, Time) 
ASCT requires the storage of HSC at ultra low temperatures for extended 
periods and the effect of storage on HSC function has been of concern since 
the 1960s and continues to be in the present day [Mannick et al., 1960, 
Cavins et al., 1962, Lewis and Trobaugh, 1964, Malinin et al., 1970, 
Buckner et al., 1970, Rybka et al., 1980, Rowley et al., 1994]. The ef-
fect of both storage temperature and length of storage have been assessed by 
numerous studies using CFU-GM assays and increasingly CD34 enumeration. 
The most effective storage conditions for HSC for prolonged periods is 
in the liquid phase of nitrogen, -196 °C, as vapour phase storage is sub-
ject to temperature fluctuations [Rybka et al., 1980]. A comparison study 
of HSC stored in liquid nitrogen with dry ice ( - 78.5 °C) storage after 3 
years [Malinin et al., 1970] reported that cells stored in liquid nitrogen were 
largely intact while those stored in dry ice were essentially destroyed. Stor-
age of HSC at low temperatures (i.e. -196 °C) should result in a complete 
and homogenous blockade of all enzymatic pathways, which should limit any 
deterioration in HSC viability [Aird et al., 1992]. A controlled retrospective 
study of the engraftment data of 33 ASCT patients whose HSC had been 
stored for 2 years or more in liquid nitrogen reported that HSC stored for up 
to 11 years was capable of engraftment [Aird et al., 1992]. 
A study into the effects of background radiation on Chinese ham-
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ster ovary fibroblasts cryopreserved in 10% DMSO and stored at -196 °C 
estimated that a time period of approximately 30,000 years was re-
quired to cause cellular destruction in HSC stored under these condi-
tions [Ashwood-Smith and Friedmann, 1979]. Consequently, as ASCT are 
only required for the life-span of the human recipient it seems unlikely that 
this would be an issue. 
Investigation of cryopreservation of cord blood HSC cells by CFU-
GM, BFU-E and CFU-GEMM assessed after 6 months, 2 and 12 years 
storage in liquid nitrogen reported no significant loss of HSC func-
tion [Mugishima et al., 1999]. This study is supported by a retrospective 
study [Attarian et al., 1996] which found no detectable deterioration of cells 
stored for up to 7.8 years. These findings suggest that HSC may be stored 
for prolonged periods at ultra low temperatures without adversely affecting 
the engraftment potential of HSC. 
1.6 Reinfusion associated toxicity 
1.6.1 Causes (DMSO, RBC's, vol. Overload, histamine) 
Cryopreserved HSC are usually thawed at or near the patient's bedside in 
a 37 °C water bath and the cells are then reinfused as quickly as possible 
into the patient [Bostrom and Burger, 1999]. Hence DMSO is routinely rein-
fused intravenously along with the thawed cell products [Egorin et al., 1998] 
and is associated with a number of dose dependent DMSO infusion re-
lated toxicities [Stroncek et al., 1991]. Many of these effects are due to 
DMSO induced histamine release by mast cells [Brayton, 1986]. The fre-
quency of ASCT side effects correlates with the volume of infused cryop-
reserved cells, the dose of DMSO and the volume of cell lysis products in-
fused [Styler et al., 1992, Okamoto et al., 1993]. 
Red blood cells lyse when frozen and thawed, resulting in renal tubule 
damage, pyrexia and hyperkalemia [Okamoto et al., 1993]. These side effects 
stimulate the endothelial cells to produce thromboplastin, which activates co-
agulation factors and induces disseminated intravascular coagulation (DIC), 
further increasing damage to kidneys [Okamoto et al., 1993]. In addition, 
complement activation and mast cell de-granulation results in the produc-
tion of histamine, leukotriene and anaphylotoxin, which can cause transient 
shock [Bostrom and Burger, 1999]. 
The presence of damaged granulocytes in cryopreserved cell solutions can 
lead to cell clumping upon thawing, which has the potential to decrease 
the number of HSCs being reinfused into the patient, which in turn could 
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affect patient recovery from ASCT. The reinfusion of histamine released by 
the dead and damaged granulocytes can trigger vasodilatation of local blood 
vessels and smooth muscle contractions, leading to demonstration of some of 
the symptoms of immediate hypersensitivity reactions [Janeway et al., 1999]. 
Fluid overload as a consequence of the reinfusion of large volumes of 
cryopreserved cells into patients is also a potential cause of reinfusion re-
lated toxicity especially for patients with renal and cardiopulmonary insuffi-
ciency [Okamoto et al., 1993, Dhodapkar et al., 1994]. 
1.6.2 Symptoms 
ASTC patients experience reinfusion related symptoms more 
than allogeneic RSC patients and these toxicities are largely re-
lated to DMSO [Stroncek et al., 1991, Lopez-Jimenez et al., 1994, 
Bostrom and Burger, 1999]. Nausea and vomiting are the most com-
monly reported side effects of ASCT [Davis et al., 1990]. However numerous 
other ASCT related symptoms have been reported with varying frequency 
including: headache, fever, abdominal cramping, flushing, decreased heart 
rate, neurological toxicity and increased blood pressure [Davis et al., 1990, 
Stroncek et al., 1991, Rowley et al., 1999b, Hoyt et al., 2000]. 
DMSO is excreted primarily via urine as dimethyl sulfone (DMS02) 
with less than 2% excreted by urea and 3% is exhaled as a metabolite, 
dimethyl sulfide (DMS) which is associated with a unpleasant "garlicky" 
odour [Brayton, 1986]. A study of 22 oncology nurses treating recipients of 
ASCT reported that 91 % of nurses had personally experienced symptoms 
such as headache and nausea following exposure to DMS. As a consequence 
they attempted to avoid odour contact and hence potentially compromised 
patient treatment [Prior et al., 2000]. As the estimated halflife of DMSO in 
man is approximately 11 to 14 hours and the half life of D MS is approxi-
mately 24 hours [Swanson, 1985] ASCT patients, their family members and 
hospital staff could be exposed to DMS side effects for a extended period of 
time. 
Kessinger etal (1990) found that of 100 ASCT patients, 92% ex-
perienced haemoglobinuria and 80% experienced red urine post reinfu-
sion of cryopreserved RSC [Kessinger et al., 1990]. Acute renal failure, 
heart attack or cardiac arrest have also been reported as a result of the 
contamination of red blood cell lysates and DMSO [Styler et al., 1992, 
Rowley et al., 1999a]. The release of histamine by DMSO or from dam-
aged granulocytes has been reported to cause various degrees of AV nodal 
conduction block [Styler et al., 1992]. Additional factors such as the me-
chanical effect of large volume reinfusion, cell lysis products such as potas-
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sium, calcium or adenosine, and hypothermia of the infused HSCs has 
also been suggested as possible cause of bradyarrhythmia in ASCT pa-
tients [Styler et al., 1992, Keung et al., 1994, Lopez-Jimenez et al., 1994]. 
1.6.3 Treatment 
The pre-medication administration of antihistamines prior to reinfusion re-
duces the ASCT symptoms related to histamine release [Davis et al., 1990] 
and most symptoms resolve over a few hours and are treated symptomati-
cally [Rowley et al., 1999a]. However those ASCT patients with renal insuf-
ficiency may require plasmapheresis post reinfusion to reduce DMSO related 
side effects if a large volume of HSC is reinfused [Dhodapkar et al., 1994]. 
Correlation between the volume of transplanted cells and hence the vol-
ume of DMSO and side effects has been demonstrated by several stud-
ies [Davii;; et al., 1990, Kessinger et al., 1990, Dhodapkar et al., 1994]. The 
maximum dose of DMSO which can be safely reinfused during ASCT is gen-
erally considered to be lg DMSO/Kg/day [Bostrom and Burger, 1999]. In 
the event that a large volume of cryopreserved cells needs to be reinfused 
the reinfusion should be conducted over two days to limit patient DMSO 
exposure [Bostrom and Burger, 1999]. 
Currently there are two main strategies for reducing ASCT related tox-
icities. Firstly the total volume of cells cryopreserved can be reduced and 
thus the volume of DMSO and cell lysis products for reinfusion will be re-
duced [Davis et al., 1990]. Increasing the NCC during cryopreservation to 5x 
108 /ml has accordingly been suggested as a means of reducing DMSO require-
ments [Rowley et al., 1994]. Secondly, DMSO and the cell lysis products can 
be removed by washing post-thawing consequently removing the suspected 
cause of ASCT related toxicities [Beaujean et al., 1991, Syme et al., 2004]. 
1. 7 Removal of Toxins prior to Transplant 
1. 7 .1 Concerns 
Previous studies have expressed concern that the removal of DMSO by wash-
ing may reduce the viability and/ or number of HSC, available for reinfusion 
and so adversely affect the engraftment potential of an ASCT. Ragab et al 
1977 reported the nucleated cell recovery of cryopreserved samples before 
washing was approximately 100%, while post washing the recovery was only 
between 30 to 50%, concluding that post-thaw washing was detrimental to 
HSC [Ragab et al., 1977]. These findings were supported by Broxmeyer et 
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al 1989 who reported an 80-100% recovery of cryopreserved nucleated cells 
before washing and concluded that any washing of cells to remove DMSO 
severely decreased the recovery rate of nucleated cells [Broxmeyer et al., 1989]. 
However Rubinstein et al 1995 have reported improved recovery of viable 
cryopreserved umbilical cord blood HSC following washing with isotonic so-
lution [Rubinstein et al., 1995]. 
1. 7 .2 Washing protocols 
The New York Cord Blood Bank (NYCBB) washing protocol as reported by 
Rubinstein et al 1995 concluded that DMSO could be removed from cryop-
reserved cord blood by washing thawed cryopreserved HSC without affecting 
the cell viability or clonogenic ability [Rubinstein et al., 1995]. Immediately 
after thawing, an equal volume of isotonic albumin/ dextran diluent solution 
is slowly added with continuous mixing before centrifugation at 400g for 10 
mins. The supernatant is then removed and the cell pellet slowly resuspended 
in fresh albumin/ dextran solution to the original volume. 
1. 8 Clinical Trial 
Although predominately used for UCB, post-thaw stem cell 
washing is an increasingly common laboratory practise prior to 
ASCT [Rubinstein et al., 1995, Antonenas et al., 2001, Syme et al., 2004, 
Lemarie et al., 2005]. However this procedure needs to be balanced against 
the fact that morbidity has already been significantly lowered by reductions 
in the reinfusion volume (achieved through refined harvesting, mobilising 
and processing techniques) and improved patient pre-medication. A formal 
clinical trial is required to properly assess whether such a the change in 
procedure significantly benefits HSC recipients. 
1.8.l Quality of Life Assessment 
Analysis of morbidity can be assessed qualitatively through the use of quality 
of life assessments (QOL). Health-related QOL refers to the extent which 
one's usual or expected physical, emotional and social well-being are af-
fected by a medical condition or it's treatment [Cella, 1996]. Since the 
1970s QOL has become central to oncology research as opposed to sim-
ply cure focussed research [Aaronson, 1990, Cella and Tulsky, 1993]. This 
reflects an understanding that a severely toxic treatment must have its 
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harmful side effects weighed against its ultimate impact on survival progno-
sis [Cella and Bonomi, 1995]. This information can then be used to evaluate 
the efficacy of competing medical interventions and as a guide to improving 
care delivery [Cella, 1996]. QOL is now so highly valued that the US Federal 
Drug Administration (FDA) has stated that benefit to QOL is one of two 
possible reasons for approval of new anticancer drugs, with improved survival 
being the other criteria [Cella, 1996]. 
1.8.2 Patient and Test Selection 
As the patient is the most authoritative source of QOL information, such 
surveys are subjective and the selection of subjects should be guided by 
statistical considerations [Aaronson, 1990] . A major consideration is the 
calculation of required sample size. This may be determined by a combina-
tion of three factors: alpha level (usually set at P < 0.05); power, or the 
probability that the study will accurately confirm the hypothesis; and effect 
size, the extent to which the phenomena under study truly differs amongst 
samples [Cella and Bonomi, 1995]. 
In addition to statistical considerations, the use of pilot studies will estab-
lish the suitability of questions for patients as well as any potential problems 
with access. Any practical concerns can then be addressed before commenc-
ing a clinical trial. Preliminary investigations may also help to clearly identify 
the population of interest and hence refine the inclusion/exclusion criteria of 
a QOL survey on the basis of relevant criteria (such as disease, treatment, 
age, gender, ... ) [Cella and Tulsky, 1993]. 
The most common issues reported in QOL surveys in oncology are pain, 
nausea and fatigue [Cella and Tulsky, 1993]. As QOL measurements are sub-
jective there is no 'gold standard' and the numerous QOL surveys available 
can be grouped into three broad categories [Cella, 1996]. 
1. Descriptive QOL information may be obtained from the use of open 
ended questions during interviews such as the Perceptual QOL, devel-
oped for the study of cancer patients following radiation therapy. 
2. Multiple choice or analogue (scaled) QOL data responses may also be 
acquired used in surveys such as the Linear Analog Self Assessment 
(LASA) developed for the general cancer patient population. 
3. A combination of both styles may be employed such as the Psychosocial 
Adjustment to Illness Scale (PAIS) for general illness [Cella and Tulsky, 1990]. 
Furthermore, in order reduce problems associated with non compliance, 
the potential burden to patients or staff must be a considered as well as 
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the ability of a particular QOL scale to meet the needs of the investiga-
tor [Cella, 1996]. An existing scale can be modified to include relevant and 
specific items not included in the scale in order to evaluate additional cri-
teria [Cella and Bonomi, 1995]. QOL surveys can be rated by an observer 
such as a health care professional or family member, however these observa-
tions do not always agree strongly with patient self ratings and therefore are 
considered to be less reliable [Cella and Tulsky, 1993]. 
1.8.3 Quality of Life Surveys and Bone Marrow Trans-
plantation 
The practitioner must weigh the benefits of the transplant versus the patients 
quality of life [Cella and Webster, 1999]. Consequently the concept of QOL 
is of interest to the area of ASCT especially in the instances where the 
procedure outcome may not always be guaranteed (as in the case of treatment 
of low grade lymphoma). Furthermore, QOL surveys have also been used to 
evaluate the impact of BMT in order to improve quality of patient care. 
A qualitative study of 119 AlloBMT patients consisting of a one-time 
interview using six open-ended questions. [Ferrel et al., 1992] demonstrated 
that four dimensions of patient well-being were affected: 
Physical: infertility, nutrition, functional activity, strength and stamina, vi-
sual disturbances/cataracts, recurrent colds, coping with chronic GVHD; 
Psychological: anxiety, second chance, depression, fear of recurrence, changed 
priorities, cognition/attention, coping with survival; 
Spiritual: hope, despair, religiousity, inner strength and 
Social: appearance, leisure activities, return to work, financial burden, roles 
and relationships, affection/sexual function. 
Further analysis of patient responses identified factors capable of influ-
encing their QOL both positively (such as good health, family and friends, 
appreciating life, ... ) and negatively (such as unfulfilled goals, losing rela-
tionships, financial distress, ... ). Moreover, patients identified areas where 
health professionals could enhance QOL including; being accessible, pro-
viding support groups and increasing patient participation in decision mak-
ing [Ferrell et al., 1992]. 
Studies of AutoBMT survivors based on the QOL methodology 
of [Ferrel et al., 1992] have found that most AutoBMT patients experi-
enced few long term side-effects and enjoyed above average QOL that was 
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equal to and sometimes superior to pre AutoBMT [Whedon et al., 1995, 
Saleh and Brockopp, 2001]. However, areas of AutoBMT patient concern in-
cluded fear of recurrence, fear of secondary cancer and sexual function as also 
identified by AlloBMT patients [Ferrel et al., 1992]. Nevertheless, a multi-
centre questionnaire study of 200 adult allogeneic (46%) and autologous 
(54%) BMT patients at least 12 months post transplant, concluded that in 
general AlloBMT patients reported poorer QOL [Andrykowski et al., 1995]. 
The use of pre- and post-BMT QOL assessments of physical, psychological 
and spiritual functioning would identify those patients requiring specialised 
assistance [Whedon et al., 1995, Saleh and Brockopp, 2001]. 
Investigation of the impact of BMT on QOL of patients has lead to im-
proved understanding and identification of patient needs. However, a study 
of 150 oncology nurses using a mailed Quality of Life-BMT Survey (used pre-
viously with patient analysing perceptions of the meaning of QOL for BMT 
patients), revealed that nursing staff believed that patients had a lower QOL 
than the patients themselves believed [King et al., 1995]. The failure to ade-
quately assess patient needs could result in a focus on physical aspects rather 
than incorporating a more holistic approach. 
1.8.4 Prior Studies of Quality of Life and Reinfusion 
Related Side-effects 
The impact of the post-thaw removal of DMSO for patients undergo-
ing ASCT has been previously evaluated by use of a visual analog scale 
QOL (VAS-QOL) questionnaire measurement of infusion related symp-
toms [Rowley et al., 1999a]. The aim of that study was to determine if in 
addition to preventing dose related DMSO toxicites, if the NYCBB washing 
protocol would remove the need for anti-histamine pre medication (such as 
diphenhydramine). 
Using a modified NYCBB washing protocol, cryopreserved cells were 
washed with 10% dextran-40 and 5% Human Serum Albumin (HSA) solu-
tion, the supernatant expressed and then transported to the patients bedside 
for immediate reinfusion. Five patients enrolled in the study completed two 
surveys, one immediately before the reinfusion and the other post reinfusion. 
The patients enrolled in the study did not receive any medication within 
2 hours preceding the ASCT. Furthermore, nursing staff attending to the 
patient also documented an assessment of patient toxicity and vital signs 
before, during and after completion of the infusion. 
However, this study was abandoned for safety reasons after 
one patient experienced severe infusion-related toxicity. Conse-
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quently, [Rowley et al., 1999a] acknowledged that anti-histamine medication 
should be part of ASCT patient care, however they recommended pre freezing 
volume reduction to reduce the quantity of cells stored and hence the amount 
of DMSO used as a more efficacious approach to reducing infusion-related 
toxicity. 
1.9 Summary 
There have been numerous developments in ASCT since its discovery 
as a consequence of the post world war two investigations into the ef-
fects of irradiation. Currently the number of autologous transplant pro-
cedures performed exceeds allogeneic procedures as increasing applications 
are found for this procedure. However, as HSCs require storage for vari-
able lengths of time before ASCT, cryopreservation is necessary in order 
to maintain cellular viability and function during storage of at ultra low 
temperatures [Apperley et al., 2000]. DMSO, a by product of the paper 
industry, is the principal cryoprotectant used in the cryopreservation of 
HSC and hence is routinely reinfused intravenously along with the thawed 
cell products [Egorin et al., 1998]. The intravenous reinfusion of cryopre-
served HSC has been associated with numerous side effects including: re-
nal failure, nausea, vomiting, headaches, cardiac and neurological com-
plications [Stroncek et al., 1991, Styler et al., 1992, Okamoto et al., 1993, 
Limaye, 1997]. The frequency of ASCT side effects correlates with the vol-
ume of infused cryopreserved cells, the dose of DMSO and the volume of cell 
lysis products infused [Styler et al., 1992, Okamoto et al., 1993]. 
Currently there are two main strategies for reducing ASCT related tox-
icities. Firstly, the total volume of cells cryopreserved can be reduced and 
thus the volume of DMSO and cell lysis products for reinfusion will be re-
duced [Davis et al., 1990]. Secondly, DMSO and the cell lysis products can 
be removed by washing post-thawing consequently removing the suspected 
cause of ASCT related toxicities [Beaujean et al., 1991, Syme et al., 2004]. 
The utilisation of post-thaw stem cell washing is an increas-
ingly common practise [Beaujean et al., 1991, Rubinstein et al., 1995, 
Antonenas et al., 2001, Syme et al., 2004], however this needs to be balanced 
against the fact that morbidity has already been significantly lowered by 
reductions in the reinfusion volume (achieved through refined harvesting, 
mobilising and processing techniques and improved patient pre-medication). 
The question this thesis will seek to answer is: does any reduction in patient 
morbidity from washing warrant use of this technique in the presence of re-
duced reinfusion volumes of DMSO? Evaluation of ASCT patient well-being 
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through the use of QOL surveys may provide a valuable assessment of the im-
pact of post-thaw stem cell washing on patient morbidity. This information 
can then be used to evaluate the efficacy of competing medical interventions 
and as a guide to improving care delivery [Cella, 1996]. 
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Project Aims 
This thesis reports on a validation study of a modified version of New York 
Cord Blood Bank's (NYCBB) washing protocol (Rubinstein et al. 1995) in 
which the rate of centrifugation was increased to 1400g. The aim of this 
modification was to improve the separation of the HSC pellet from the su-
pernatant to reduce cell loss during plasma expression. Increasing centrifuge 
speed will increase the sedimentation rate and the density of the cell pellet, 
raising the spectre of damage to HSC because of this adjustment. Therefore 
the principal aim of the laboratory study was to carefully and thoroughly 
validate the impact of the washing procedure on the efficacy and safety 
of HSC transplantation. This was accomplished through multi-parameter 
analysis of the cell recovery [Hartmann et al., 1985] and engraftment poten-
tial [Spitzer et al., 1980, Chang and Ma, 1998] of washed and unwashed sam-
ples. 
This thesis also presents findings of a clinical trial using a modified version 
of the VAS-QOL surveys [Rowley et al., 1999a] in which all patients enrolled 
in our non-randomised trial received pre medication prior to ASCT. The pri-
mary objective of this study is to determine whether washing of thawed HSC 
products is clinically justified. This is achieved by measuring the morbidity 
experienced by patients who receive Washed HSC as well as those patients 
who receive Unwashed HSC. Patients enrolled in this study completed four 
VAS-QOL surveys at pre-determined intervals within 24 hours of ASCT. 
In addition, as the majority of reinfusions are performed in the outpatient 
setting where care of the patient by family members supplements nursing 
staff, we studied the impact of the washing protocol on the side effects expe-
rienced by nurses and carers. If this study validates the efficacy of the wash-
ing procedure in a clinical setting, then it will potentially lead to improved 
patient comfort (and collaterally nursing and family members) through the 
safe removal of toxic compounds in stem cell harvests. 
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Chapter 2 
Laboratory Validation 
2.1 Introduction 
The aim of this laboratory validation study was to investigate if toxic D MSO 
and cell lysis products can be safely washed out from thawed stem cell har-
vests without affecting stem cell viability and engraftment potential using 
standardised and reproducible multiple parameter testing. Cellular pellets 
spun at 400g were found to be relatively "soft" and thus were prone to 
dislodging during plasma expression. Therefore the centrifuge speed was in-
creased to 1400g to harden the pellet and reduce the risk of cell loss during 
plasma expression. 
The results of the multiple parameter testing will provide an accurate 
record of the impact of the washing protocol on HSC viability and engraft-
ment potential. In addition, the impact of the washing protocol on free 
haemoglobin levels will indicate its effectiveness in removing cellular lysis 
products, and by association, DMSO. This modified HSC washing protocol 
will demonstrate whether this is a feasible clinical practice that has the poten-
tial to reduce the morbidity associated with the reinfusion of cryopreserved 
stem cells. 
2.2 Materials and Methods 
2.2.1 Maintenance of Sterility 
Sterility was maintained with a Class II Biological Safety Cabinet where 
required. 
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Table 2.1: Reagents and Suppliers 
I Reagents 
0.9 % Saline Infusion BP AHB 1323 
7-AAD 
ACD-A AHB7898 
ProCOUNT 340498 
20% Human Serum Albumin (HSA) 
Gentran 40 Dextran 40 I. V Infusion 
BP 10% w/v in NaCl l.V. Infusion 
BP 0.9 w /v B5043 
Methocult(tm)1GF 4534 
(Batches HC8L05T037 and HC9B19R038) 
Monoclonal antibodies2 
Anti-HPCA-2 CD34 PE 348057 
Anti-HLe-1 CD45 FITC 34 7 463 
Isotype Control: Mouse lgG 1 PE 349043 
PBS tablets BR0014G 
Suppliers 
Baxter 
Sigma Chemical Company 
Baxter Fenwal 
Becton Dickinson 
CSL Ltd 
Baxter 
AMRAD Pharmacia 
Becton Dickinson 
Becton Dickinson 
Becton Dickinson 
Oxoid 
Optilyse B 1400 Immunotech 
Trypan Blue (0.4% solution, P04 buffered NaCl) ICN 
16-910-49 
2.2.2 Solutions 
Isotonic Diluent Solution 
Gentran 500 ml 
Saline 400 ml 
HSA 100 ml 
Components were mixed and stored at 4 °C. 
PBS 
10 PBS tablets were dissolved in de-ionised distilled water and made up to 
lOOOml with distilled water. PBS solutions were filtered and stored at 4 °C. 
1 Methocult batches underwent testing for batch-to-batch variability as part of the Stem 
Cell Transplant Laboratory, Royal Hobart Hospital, routine quality control. 
2 All antibodies used had undergone verification of reactivity as part of routine Quality 
Assurance in the Flow Cytometry Laboratory, Royal Hobart Hospital. 
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Table 2.2: Disposables and Manufacturers 
I Disposables 
10 ml syringe with Luer lock SS+ lOL 
18 G Drawing up needle, non-bevelled 04038088 
30ml sterile V bottom containers 10425003 
3ml syringe with Luer lock 302113 
60 ml syringe with Luer lock SS60LA 
600ml Fenwal Transfer pack container with coupler 4R2023 
Coupler with female Luer 912-647-904 
Falcon tube with cap (sterile) 352058 
Hemastix 2816 
Mixing Cannulae 500.11.012 
Petri dish ( 35 x 10 mm with 2 mm grid) 17 4926 
Table 2.3: Equipment and Manufacturers 
I Equipment Manufacturers 
4 well plate Corning 
400 Cyclic Fridge Kelvinator 
Manufacturers 
Terumo 
Braun 
Techno-Plas 
Becton Dickinson 
Terumo 
Baxter 
Co be 
Imbros Pty Ltd 
Bayer 
Indoplas 
Corning 
Class II Biological Safety Cabinet Gelman Sciences Australia 
FACScan Flow Cytometer Becton Dickinson 
Haemocytometer (O.lmm2) Superior 
Incubator (5% C02) Heraeus Instruments 
Inverted Microscope Olympus 
Microfuge Denver Instruments 
PB 3000 Scales Mettler 
Plasma Extractor 
RF Sealer Model 2101 
Varifuge 3.0RS 
Vortex mixer 
Water bath 
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Fenwal 
Se bra 
Heraeus Instruments 
Ratek Instruments 
Ratek Instruments 
Stock 7 AAD Solution 
7AAD 1 mg 
DMSO 0.5 ml 
PBS 0.5 ml 
A stock solution was prepared by dissolving the 7 AAD in DMSO and 
then in PBS. To make the working solution, 975µL of PBS was added to 
25µL of 7 AAD stock solution (final concentration 25g/ml), which was then 
aliquoted into tubes. One tube of the working solution was stored at 4 °C 
in the dark, and the remainder of the aliquots were stored at -20 °C until 
required . 
. 2.2.3 Study Samples 
Ethical Approval 
Approval for this study was obtained from the University of Tasmania Human 
Research Ethics Committee (Project No. 9844). 
Selection of the study samples 
Fourteen frozen cryobags containing stem cell collections from deceased pa-
tients (seven bone marrow harvests and seven peripheral blood harvests) 
were used for this laboratory validation study. All study samples had been 
harvested and processed at the RHH between 1997 and 1998 and stored in 
the liquid phase of liquid nitrogen until transfer to storage in the Stem Cell 
Laboratory -80 °C freezer immediately prior to the time of this study. 
2.2.4 Stem Cell Washing Protocol 
Fourteen frozen cryobags containing stem cell collections from deceased pa-
tients (seven bone marrow harvests and seven peripheral blood harvests) 
were rapidly thawed in a water bath at 37 °C. Using aseptic techniques, the 
bags were spiked with a blood pack adaptor and a lOml Unwashed sam-
ple was removed for testing (Fig 2.1). An equal volume of freshly prepared 
sterile isotonic diluent (5% dextran, 2% HSA in saline) was slowly added to 
the cryobag, with constant mixing, and the diluted cells transferred into a 
600ml Baxter Fenwal 4R 2024 bag suitable for centrifuging, at 1400g for 10 
minutes to pellet the cells. The speed of centrifugation was increased from 
the published 400g [Rubinstein et al., 1995], in order to improve separation 
of the cellular pellet and supernatant and reduce cellular loss during plasma 
expression. The supernatant, consisting of the DMSO cryopreservative and 
29 
Figure 2.1 Experimental Design 
Frozen Cryobag Thawed 37C Waterbath 
Cell Counts & Viability 
CD34 Analysis 
CFU-GM Assay I Withdraw 1 Omls "Unwashed" 
4111 
l 
Free Haemoglobin 
l 
Add equal volume 
... 
Isotonic Diluent Solution 
Isotonic Diluent Solution 
Discard Supernatant Removed 
4111 
Supernatant 
Cell Pellet 
l 
Add Isotonic Diluent Solution 
... 
to resuspend cell pellet 
Isotonic Diluent Solution 
Cell Counts & Viability 
CD34 Analysis 
CFU-GM Assay D 
1 Omls "Washed" 
Withdraw 10mls "Washed" 
4111 
l 
Washed, resupended cells 
Free Haemoglobin 
toxic cell lysis products, was removed by manual plasma expression and the 
cells resuspended in fresh dextran/saline to the original volume. Lastly, a 
lOml Washed sample was removed for testing. The details of all reagents, 
disposables and equipment used in this laboratory validation are listed in 
Tables 2.1, 2.2 and 2.3 respectively. 
Experimental Methods 
Due to the logistics of simultaneously performing all assays at all time points, 
not all assays were performed on all bags. Sufficient repeats of each assay 
were performed in order to power the comparisons to the satisfaction of the 
statistician (Dr Wotherspoon). 
Using time course the following parameters were investigated in the Un-
washed and Washed samples at thirty minute time intervals for a period of 
ninety minutes; cell loss, overall viability, viable CD34+stem cell enumera-
tion, clonogenic potential and reduction in free haemoglobin content. 
Cell counts and viability 
At each time interval, a manual total cell count and cell viability was per-
formed on a 1:100 dilution of samples and isotonic diluent solution. A manual 
cell count was then performed using a haemocytometer on a 1:1 dilution of 
cells to Trypan Blue solution. 
Viable CD34+stem cell enumeration 
Using the total cell count obtained above, an appropriate sample dilution 
was prepared to obtain a volume of less than lOOµL containing 8 x 105 nu-
cleated cells. This was added to an Eppendorf tube containing fluorescently 
labelled monoclonal antibodies (lOµL each of eD45-FITC and CD34-PE), 
and lOµL of 7-AAD. A negative control tube was prepared identically except 
the anti-eD34 was substituted with an isotype control, IgGl-PE. Samples 
were incubated at room temperature in the dark for 15 minutes prior to ad-
dition of lOOul Optilyse B. After an additional 10 minutes incubation, lml 
distilled water was added. The samples were then incubated for another 10 
minutes before immediate flow cytometric analysis. 
A known concentration of ProCOUNT (Becton Dickinson) fluorospheres 
was added to each tube immediately prior to the addition of sample. This 
established a ratio of fluorospheres to the original volume of the sam-
ple, thus enabling the absolute CD34+cell count to be calculated while 
eliminating the need for a wee from a automated haematology anal-
yser hence improving test reproducibility as well as the need to include 
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sample volume [Keeney et al., 1998, Chang and Ma, 1998, Rock et al., 2000, 
Dickinson and Company, 2003]. The incorporation of viability dyes such as 
7 AAD into single platform analysis allowed the determination of the absolute 
viable CD34+cell count [Keeney et al., 1998]. Well-mixed samples were anal-
ysed using a Becton Dickinson FACScan flow cytometer with the CellQuest 
software package. 
Through a series of sequential gates viable CD34+stem cells are distin-
guished from all other cellular events by firstly identifying leucocytes, sec-
ondly viable leucocytes and finally viable CD34+stem cells. The gating strat-
egy is listed here in progressive order: 
1. Viable CD34 +events present in Washed and Unwashed samples were 
isolated from other cellular and non-specific stained events because of 
a series of progressive logical gates (Fig. 2.2). The first histogram plot 
(plot 1) displays forward scatter vs side scatter for all events in which 
region 1 (Rl) was set to include all cellular events. Plot 2 displays 
CD45+ events versus side scatter, with R2 set to collect all CD45+ events 
(i.e. leucocytes). 
2. The first logical gate (Gl) was set to include all of Rl and R2 and plot 
3 was drawn using this gate. R3 was set to exclude dead cells, which 
stained with 7-AAD. These three regions were set by initially running 
samples in set-up mode prior to acquisition. 
3. Viable leucocytes gated from Rl, R2 and R3 are displayed in plot 
4, which displays CD45+vs CD34+events, and R4 was set to select 
CD34+ssc low events. Plot 5 displays CD45 versus SSC characteristics 
of CD34+cells gated from additive regions 1-4. Any remaining non-
specifically stained events such as debris, platelets and mature cells 
are excluded in R5 and so this region was set to select cells forming 
a cluster with the characteristic low SSC and low-intermediate CD45 
fluorescence of HSC. The light scatter characteristics of the cells from 
additive regions 1-5 were displayed in plot 6, and R6 was set in the 
lymphoblastic region in order to isolate the cluster of events which 
fulfilled all the fluorescence and light scatter criteria of the CD34+HSC. 
The number of events in R6 was used for the calculation of the absolute 
CD34+cell count. 
4. Single-bead events were collected into R7, which was set to only dis-
play the fluorospheres vs time, as prescribed by the manufacturer. The 
control sample was analysed using the same gating strategy. The cal-
culation for absolute CD34+was performed as per the instructions of 
the manufacturer [Dickinson and Company, 2003]. 
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Figure 2.2:Representative Example of Flow Cytometry Gating Strategy and Analysis for CD34+ events 
5. The absolute CD34+cell count per µL for each sample was calculated 
as follows: 
cn34+ 
µL 
#CD34+events(R5) . . . 
#b d d(R?) x bead concentration x dilution factor 
ea s counte 
The same calculation was also performed on the control sample to de-
termine the level of non-specific background staining. The CD34 +cell 
count/ µL was calculated from the test samples, and the absolute CD34+ 
cell count was determined by subtracting the control sample result from 
this value. 
CFU-GM Clonogenic Assays 
CFU-GM assays were performed on the Washed and Unwashed samples to 
assess the clonogenic potential. CFU-GM assays were set up in duplicate 
for both Washed and Unwashed samples at thirty-minute intervals over a 
ninety-minute period post-thawing. 
Using the total viable cell count obtained from the manual cell count, an 
appropriate sample dilution was prepared to obtain aliquots containing 20 
OOO or 50 OOO viable nucleated cells (depending on cell numbers) in 300µL 
volume. This was added to 1 ml of Methocult GFH4534 (Stem Cell Tech-
nologies), a commercially available, semi-solid medium containing recombi-
nant cytokines, and 1.1 ml plated onto duplicate gridded 35mm diameter 
petri dishes and incubated for 14 days at 37 °C in a humidified atmosphere 
containing 53 C02 • Colonies were defined as clusters of 30 cells and were 
identified using an inverted microscope. The results obtained were used to 
calculate the mean number of CFU-GM per 104 viable nucleated cells. 
The total number of CFU-GM in the harvest was calculated as follows: 
~ l CFU-GM = Mean CFU-GM % viability TNC 
ota 104 VN C x 100 x 1Q4 
where VNC is the viable nucleated cells and TNC is the total nucleated cells 
of the final product. 
Free Haemoglobin Content 
Assessments of free haemoglobin levels were performed on cell-free super-
natants of Washed and Unwashed samples following centrifugation at 7000g 
for thirty seconds in a microfuge. Dipstick analysis (Hemastix, Bayer) was 
performed on 1:25000 dilution (isotonic diluent solution) of the supernatant 
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Table 2.4: Free Haemoglobin 
Free Haemoglobin Score 
(Red Cell Equivalent/ uL) 
< 25 1 
25-80 2 
80 3 
80 - 200 4 
> 200 5 
and the results (in red cell equivalent/ul) read after 60 seconds. Categories 
were assigned to diluted haemoglobin levels, as indicated in Table 2.4, to 
allow Sign test statistical analysis. 
Statistical Analysis 
Ms Imagen Liew, University of Tasmania provided statistical advice and 
guidance. Univariate and Student's paired t-test statistical analysis was per-
formed on sample data with the criterion for significance determined as a p 
value of P < 0.05. 
2.3 Results 
2.3.1 Loss of Cells During Washing Procedure 
The rate of centrifugation was increased from 400 g to 1400g in order reduce 
the potential for cell losses by improving the separation between the cell 
pellet and supernatant. Manual cell counts (using Trypan Blue solution) 
were obtained immediately post-manipulation in order to assess the effect 
of the washing protocol on cell numbers for Unwashed and Washed samples 
(Table 2.5), where PBSC is Peripheral Blood Stem Cell Collection and BMH 
is Bone Marrow Harvest. 
Student's paired t-test analysis of the data demonstrated no significant 
difference cell counts between Washed and Unwashed cells (p = 0.10) as 
displayed in Table 2.5. Further analysis found no significant difference ex-
isted between samples obtained from BMH (p = 0.30) or PBSC (p = 0.30) 
harvests. The average recovery of cells of 95 + 8.0% confirmed these find-
ings. Therefore, the washing protocol did not result in significant loss of 
cell numbers whilst centrifugation at 1400g improved the separation of the 
supernatant and cell pellet. 
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Table 2.5: Comparison of Total Nucleated Cells ( x 108 ) for samples post-
thawing. 
PBSC BMH 
Unwashed Washed Unwashed Washed 
343.2 351.0 126.9 112.5 
284.7 240.5 107.7 115.7 
325.5 299.5 60.5 59.4 
317.2 322.4 345.6 292.8 
66.6 60.7 
309.4 319.8 
p = 0.30 p = 0.30 
p= 0.1 
As there was no difference between PBSC and BMH these values were 
combined in subsequent analysis except where noted. 
Viability of Cells After Washing 
The changes in total cell viability percentage values using time course ( com-
mencing immediately post-thawing) for both Washed and Unwashed samples 
are shown in Table 2.6. 
The viability of Washed and Unwashed cells, compared by Student's 
paired t-test analysis on samples at thirty-minute intervals over a ninety-
minute period, shows that at each time point, viability is improved for 
Washed samples. The average of each time point shown in Figure 2.3 shows 
strong evidence of improved viability of Washed cells in comparison to Un-
washed cells over time (p = 0.018). Under univariate analysis, the rate of loss 
of viability is also significantly less in Washed cells compared to in Unwashed 
cells (p = 0.005) indicating that Washed cells are dying at a slower rate than 
their Unwashed counterparts. 
Although not measured in a quantitative manner, the incidence of cell 
clumping was visually assessed to be reduced in the Washed samples in com-
parison to the Unwashed samples. Although this is at best a qualitative 
observation, decreased clumping of Washed cells does correlate with their 
increased viability. 
In conclusion, cryopreserved stem cells that were Washed with an isotonic 
diluent solution exhibited improved viability and a slower rate of subsequent 
death compared to Unwashed controls. 
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Figure 2.3:Comvarison ofNucleated Cell Viability of Washed and Unwashed Products 
Thawed cells were either Washed as per Methods (solid line) or left Unwashed (dashed line) 
and stained with Trypan Blue. Viable and non-viable cells were enumerated using a 
haemocytometer. Results shown are Mean ± SD of 10 experiments. There is a significant 
increase (p = 0.005) in nucleated cell viability in Washed samples in comparison to Unwashed 
samples. 
Table 2.6: Comparison of the percentage viability for Washed and Unwashed 
samples at each time point. 
Immediately 30 mins 60 mins 90 mins 
post-thaw Unwashed Washed Unwashed Washed Unwashed Washed 
65.9 41.6 68.0 43.4 41.6 25.8 55.0 
63.7 43.8 47.9 38.6 43.8 26.6 49.6 
61.0 49.0 49.0 36.0 49.0 22.0 58.0 
71.0 42.0 52.0 32.0 42.0 23.0 49.0 
63.0 44.8 56.0 44.9 44.8 34.6 46.6 
82.6 82.0 87.2 63.5 82.0 61.8 69.2 
69.1 64.0 64.0 52.0 64.0 42.3 55.9 
56.1 59.8 57.1 57.6 59.8 58.0 58.7 
55.0 41.0 43.0 25.0 41.0 22.0 51.0 
73.0 36.0 69.0 26.0 69.0 29.0 69.0 
p value < 0.05 < 0.001 < 0.001 
2.3.2 Enumeration of Viable CD34+Haematopoietic Stem 
Cell 
The next step was to establish if the improved cellular viability extended to 
HSCs by enumeration of viable CD34+stem cells. Using single platform flow 
cytometry, the number of viable CD34+stem cells was determined in Washed 
and Unwashed samples. Testing was performed at thirty-minute intervals 
post-thawing over a ninety-minute period (Table 2.7). The numbers shown 
in Table 2.7 represent the total number of CD34+HSC (x 106 ) present in 
the entire Washed and Unwashed harvests. The effect of washing on the 
number of viable CD34+HSC viability was assessed by paired t-test analysis 
and multivariate analysis of variance. 
Student's paired t-test analysis of the absolute CD34+numbers at each 
time point shows that, although there was no significant difference between 
Washed and Unwashed samples (Table 2.7), the differences at latter time 
points suggests a trend towards enhanced CD34 viability in Washed samples. 
However, further analysis of the data using multi-variate analysis shows that 
the difference in absolute numbers of CD34+stem cells in the Washed and 
Unwashed cells was not statistically significant (p = 0.998), indicating that 
washing did not reduce the number of viable CD34+ cells relative to Unwashed 
controls. 
Figure 2.4 represents the average percentage of original viable CD34+cells 
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Figure 2.4:Percentage Changes in Viable CD34+ Stem Cell Content Over Time. 
Thawed cells were either washed as per Methods (solid line) or left Unwashed (dashed line) and 
viable CD34+ HSC enumerated using single platform flow cytometry. The changes in the 
number of viable CD34+ HSC are expressed as a percentage of the original count immediately 
post-thawing. Results shown are Mean± SD of 7 experiments. Using univariate analysis there 
is no evidence of a difference in CD34 counts between treatments (p = 0.998). 
over time. For graphical purposes, the immediate post-thaw samples were 
enumerated for CD34+cells and this value was designated as 100% and the 
subsequent 30, 60, 90 minutes CD34+cell counts are expressed as a percentage 
of the immediate post-thaw CD34+HSC count. Figure 2.4 demonstrates 
that the difference in the average percentage of original CD34 +counts for 
the Washed and Unwashed cells over time was minimal for the early time 
points, although there does appear to be a trend towards improved viability 
for Washed CD34+cells with time. However, multi-variate analysis shows 
evidence of a constant rate of decrease in the CD34 +count over time (p = 
0.002) indicating that stem cells continue to lose viability post-thawing. 
In conclusion, the washing protocol does not diminish viable CD34 +HSC 
numbers in comparison to Unwashed cells, indicating that HSC viability is 
not adversely affected by the washing of thawed harvests. Furthermore, the 
trend towards significance in absolute viable CD34+HSC counts over time 
between Washed and Unwashed samples, suggests washing may improve the 
viability of CD34+HSC. 
2.3.3 CFU-GM Assays 
Although viable CD34+HSC numbers were not adversely affected by the 
washing of thawed HSC harvests, it was also necessary to assess the impact of 
the washing protocol on the clonogenic potential of HSC. This was assessed 
by CFU-GM assays that were performed at thirty-minute intervals post-
thawing over a ninety-minute period (Table 2.8) and the data analysed by 
Student's paired t-test analysis and multivariate analysis of variance. The 
numbers shown in Table 2.8 represent the total number of CFU-GM present 
in the entire Washed and Unwashed harvests tested. 
Student's paired t-test analysis of absolute CFU-GM assay values at each 
time point, suggests that although there is no significant difference at any 
of the time points (p > 0.05), there is a trend towards significance from the 
sixty-minute time point onwards (Table 2.8). Multivariate analysis confirms 
that the difference in CFU-GM formation between Washed and Unwashed 
cells over time is not statistically significant (p = 0.686). 
Figure 2.5 displays the average relative percentage of CFU-GM values 
over time in relation to the immediate post-thaw CFU-GM value that was 
designated as 100%. This figure illustrates that the difference in counts 
for the Washed and Unwashed cells over time was minimal for the early 
time points. However, Washed CFU-GM values do appear to improve with 
time (relative to Unwashed cells) as noted with the statistical analysis of the 
absolute numbers. 
In summary, the washing protocol does not have a detrimental affect on 
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Figure 2.5: Percentage Changes in CFU-GM Formation Over Time 
Thawed cells were either washed as per Methods (solid line) or left Unwashed (dashed line) and 
placed into CFU-GM cultures, which were enumerated after 14 days incubation. The changes 
in the number of CFU-GM recovered are expressed as a percentage of the sample taken 
immediately post-thawing. Results shown are Mean ± SD of 5 experiments. The observed 
difference in CFU-GM formation between washed and unwashed cells was not statistically 
significant (p = 0.686). 
Table 2.7: Comparison of total viable numbers of CD34+(x106 ) HSC for 
entire Washed and Unwashed harvests at each time point. 
Immediately 30 mins 60 mins 90 mins 
post-thaw Unwashed Washed Unwashed Washed Unwashed Washed 
409.3 295.4 323.1 253.4 312.7 216.0 301.1 
26.37 20.7 25.6 ...... 24.3 12.4 24.8 
66.7 65.5 67.6 57.7 70.9 33.5 58.1 
60.5 47.9 49.8 27.9 30.6 13.4 28.1 
103.8 51.5 67.4 34.3 56.2 50.8 49.7 
302.8 274.3 319.0 340.5 359.2 224.7 285.4 
75.5 70.9 38.9 26.9 33.7 24.8 22.9 
p value 0.30 0.06 0.07 
Table 2.8: Comparison of total numbers of CFU-GM ( x 105) for entire 
Washed and Unwashed harvests at each time point 
Immediately 30 mins 60 mins 90 mins 
post-thaw Unwashed Washed Unwashed Washed Unwashed Washed 
62.5 47.0 41.0 31.0 42.0 31.0 43.0 
56.0 19.9 51.5 19.9 45.1 7.7 44.3 
221.1 173.3 233.4 140.2 204.4 116.0 169.0 
97.7 101.2 85.4 65.8 65.0 46.5 43.9 
167.9 144.5 117.3 92.0 114.4 44.1 107.1 
p value 0.63 0.09 0.06 
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the potential of committed myeloid markers (a surrogate indicator of HSC 
functionality) to proliferate relative to Unwashed controls. Moreover, the 
results indicate that washing may even improve the ability of the HSCs to 
engraft and mature into macrophages and granulocytes, in comparison to 
Unwashed controls after sixty minutes post-thawing, as indicated by the 
trend towards significance. 
2.3.4 Reduction in Free Haemoglobin 
The effectiveness of the washing protocol to remove free haemoglobin from 
bone marrow harvest and peripheral blood stem cell collections was assessed 
by comparing the amount of haemoglobin present in the supernatant of 
Washed and Unwashed samples. Supernatants were diluted 1/25000 prior to 
analysis. The results were separated into bone marrow harvest and periph-
eral blood stem cell collections as the red cell concentration of bone marrow 
harvests was usually greater. 
Free haemoglobin levels in both Washed bone marrow and peripheral 
blood stem cell harvests were significantly reduced in comparison to Un-
washed supernatants (p =< 0.05, Sign Test). As can be seen in Figure 
2.6, Unwashed bone marrow harvests contained greater amounts of free 
haemoglobin than the Unwashed peripheral blood stem cell harvests and 
washing achieved significant reductions in the haemoglobin content of both 
stem cell sources. On average, a 4-fold reduction in free haemoglobin was 
achieved for bone marrow harvests and 3.6-fold reduction for peripheral blood 
stem cell collections. However as several bone marrow samples were recorded 
as > 200 RCE/ul (the upper limit of the dipstick test) and would have re-
quired further dilution, the degree of reduction for bone marrow harvests 
was most likely underestimated. However, as the levels of free haemoglobin 
were clearly reduced in Washed samples further dilution was not deemed 
necessary. 
Figure 2.7 compares the free haemoglobin scores of the Unwashed and 
Washed supernatants for each individual sample illustrating the general trend 
in free haemoglobin reduction after washing. 
In summary, washing of stem cell products achieved a significant reduc-
tion in the amount of free haemoglobin present in the supernatants of both 
thawed bone marrow and peripheral blood harvests. 
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Figure 2.6: Free Haemoglobin Content of Washed and Unwashed Bone Marrow and PBSC Harvests. 
Cell-free supernatants were created from samples taken immediately post-thawing (unwashed, solid 
column) and post-washing (washed, large dotted column) and diluted 1/25000. Free haemoglobin (in 
Red Cell Equivalent /ul) was measured in the diluted specimens using a dipstick test. Results shown are 
Mean ± SD of 7 experiments for both bone marrow and PBSC harvests. 
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Figure 2. 7: Free Haemoglobin Score of Washed and 
Unwashed Bone Marrow and PBSC Harvests. 
Cell-free supematants were created from samples taken immediately post-thawing 
(unwashed, solid column) and post-washing (washed, large dotted column) and diluted 
1125000. Free haemoglobin (in Red Cell Equivalent /ul) was measured in the diluted 
specimens using a dipstick test and was assigned a Free Haemoglobulin Score. Results 
shown are of 7 experiments for both bone marrow and PBSC harvests. 
2.4 Discussion 
Autologous HSC transplantation involves the intravenous infusion of HSC 
collected from the patient's own bone marrow or peripheral blood to replenish 
haematopoietic cell function after high dose chemotherapy [Armitage, 1994]. 
DMSO, a cryoprotectant, is added to cells prior to cryopreservation and sub-
sequent storage in liquid nitrogen to protect the cell membrane integrity by 
preventing the formation of ice crystals [Rowley, 1992]. Consequently, when 
the patient is reinfused they receive DMSO along with ruptured granulo-
cytes and red cell debris (DMSO poorly preserves these cells). The infusion 
of cryopreserved cells has been associated with a number of DMSO and cel-
lular lysis related toxicities including nausea, vomiting, acute renal failure, 
and cardiac and pulmonary arrest [Davis et al., 1990]. The washing of HSC 
post-thawing may reduce these side effects through the removal of DMSO 
and cellular lysis products. Nonetheless, before such a procedure can be 
implemented, validation studies are mandatory. 
Validation studies are crucial because any amendments to a clinical prac-
tice require elucidation of all consequences of the modifications. Regula-
tory bodies such as the National Pathology Accreditation Advisory Council 
(NPAAC) and the National Association of Testing Authorities (NATA) also 
require documentation of the validation procedures for any changes, prior to 
implementation as part of their accreditation process. Approval from these 
bodies is required for laboratory operation. 
This chapter reports on a validation study of a washing protocol in which 
the rate of centrifugation was increased to 1400g to improve the separa-
tion of the HSC pellets from the supernatant in order to reduce cell loss 
during plasma expression. The NYCBB washing protocol described by Ru-
binstein et al. 1995 concluded that DMSO could be removed from thawed 
cryopreserved cord blood by washing without affecting HSC cell viability 
or clonogenic ability following centrifugation at 400g. However cell loss re-
mained a concern with this protocol with one study reporting a median loss 
of 27.23 (range 11.1 to 41.2%) of total nuclear cells in a study of 12 cord 
bloods [Antonenas et al., 2001]. The increased centrifuge speed used in this 
investigation resulted in improved sedimentation of cells, increased density 
of the cell pellets, and hence overall improved separation of cell pellets from 
supernatant. As desired, the removal of the supernatant (containing DMSO, 
red cell debris and ruptured granulocytes) by plasma expression was achieved 
without disturbing the cell pellets. 
The increase in centrifugation rate however raised the spectre of dam-
age to HSC, therefore, multi-parameter testing was used to determine 
the impact of the revised washing protocol. Cell recoveries and viabili-
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ties [Hartmann et al., 1985] were assessed by manual cells counts, while the 
impact on engraftment potential [Spitzer et al., 1980, Audet et al., 1998] was 
measured by viable CD34+HSC enumeration and CFU-GM assays of Washed 
and Unwashed samples. The effectiveness of the washing protocol to remove 
contaminants such as DMSO, red cell debris and ruptured granulocytes was 
assessed by the measurement of free haemoglobin in Washed and Unwashed 
samples. 
The effect of the modified washing protocol on total cell numbers was 
assessed by manual cell counts on Washed and Unwashed samples. The 
findings of this study compare with the findings of Rubinstein et al.1995 
which reported no significant difference in nucleated cell count after washing 
using the NYCBB washing protocol. Previous studies [Ragab et al., 1977, 
Broxmeyer et al., 1989] have expressed concern that the removal of DMSO 
by washing may reduce the number of HSCs available for reinfusion. This 
study allays these fears by demonstrating that there is no significant loss of 
cell numbers using the revised washing protocol. Moreover, the observation 
that washing preserves the viability of cells over a ninety-minute interval 
compared to Unwashed cells extends the findings of Rubinstein etal 1995 who 
used a single time-point. Thus, this study demonstrates that the removal of 
DMSO, lysed red cells and ruptured granulocytes, in conjunction with the 
re-suspension of stem cells in isotonic diluent solution significantly improves 
the viability of stem cells post-thawing. 
As the measurement of cell clumping by quantitative methods was not 
possible, the impact of the washing protocol on cell clumping could only be 
assessed qualitatively. The reduction in cell clumping in Washed cells ob-
served in comparison to Unwashed cells in this study suggested the ruptured 
granulocytes are removed by the washing process. Cell losses of up to 50% 
have been reported in the presence of damaged granulocytes [Rowley, 1992] 
demonstrating that clumping has the potential to detrimentally reduce the 
dosage of HSCs reinfused to patients. Furthermore, the release of contents of 
the ruptured granulocytes (such as histamine) has been linked to reinfusion 
related toxicities [Okamoto et al., 1993]. The washing protocol has the po-
tential to reduce the loss of HSCs through cell clumping as well as toxicities 
related to the reinfusion of ruptured granulocytes and so improves on current 
practice. 
The enumeration of CD34+HSC is routinely used to assess the engraft-
ment potential of stem cell collections [Keeney et al., 1998]. The finding of 
no significant difference in viable CD34+HSC counts between Washed and 
Unwashed cells demonstrates that the increased centrifugal speed does not 
adversely affect viable RSC numbers. The average percentage change over 
time in the post-thaw CD34+HSC count was used for graphical presentation 
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in this study as the CD34+HSC content of the individual harvests tested 
varied immensely (from adequate HSC numbers for engraftment to grossly 
insufficient). 
The trend towards significantly improved viability of the Washed sam-
ples from the sixty minute time points suggests that washing may in fact 
improve the viable CD34+numbers relative to Unwashed cells. These find-
ings provide further demonstration of the safety of the modified washing 
protocol as well as the possibility that it may improve the viability of HSC 
post-thawing. Whilst testing of additional harvests may demonstrate a sig-
nificant difference over time for Washed samples, the purpose of this study 
was to demonstrate that the washing protocol did not adversely affect HSC. 
Ultimately this study therefore represents an improvement upon the origi-
nal study [Rubinstein et al., 1995], which did not perform viable CD34+HsC 
analysis. 
Colony Forming Units Granulocyte Macrophage (CFU-GM) assays are 
routinely performed as an in-vitro measure of the haematopoietic progenitor 
content of a stem cell collection [Eaves and Lambie, 1995]. In this study, 
the difference in CFU-GM formation between Washed and Unwashed cells 
was not statistically significant. The absolute values of CFU-GM assays of 
the harvests used in this study were also reported as the average percentage 
change in the original post-thaw value over time for graphical representation 
because of the dramatic variation between the individual harvests tested. 
The trend towards significance of the Washed samples from the sixty 
minute time points suggests that washing may in fact improve the CFU-
GM assays of Washed relative to Unwashed cells. The performance of addi-
tional testing may confirm a significant improvement in clonogenic potential 
of Washed over time, however as stated earlier, this was not the aim of the 
study. When taken together with the results of the Rubinstein etal 1995 
study, which reported that the clonogenic activity of HSC post washing was 
improved by the removal of DMSO, the data demonstrates that this proce-
dure will not adversely affect clonogenic potential. 
To avoid DMSO-related post-thaw toxicity to 
HSC [Bostrom and Burger, 1999], conventional HSC reinfusions occur 
within minutes of thawing. This study shows significant improvement of 
overall cell viability as well as a trend towards improving viable CD34+and 
CFU-GM recovery over time indicating that washing reduces the rate of 
cell loss and cell death. The modified washing protocol should therefore be 
considered as a cell-saving strategy in the event of an unexpected delay ( e.g 
loss of central line) of reinfusion of thawed products. 
The dramatic reduction of free haemoglobin levels in Washed sam-
ples is a consequence of the removal of red blood cell debris from the 
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cryopreserved stem cell product. As this study was unable to measure 
DMSO directly by gas chromatography, free haemoglobin was used as a 
surrogate marker of dilutional effects. Therefore by extrapolation of the 
free haemoglobin results, the DMSO concentration must also be accord-
ingly reduced. Furthermore, the findings of this study support the es-
timation of Rowley et al 1999 that the NYCBB washing protocol re-
moved 90% of DMSO from cryopreserved stem cells. Kessinger et al., 
1990 found that of 100 patients, 92% experienced haemoglobinuria and 64% 
experienced vomiting post reinfusion of cryopreserved HSC. Several stud-
ies of autologous haematopoietic stem cell transplantation related toxici-
ties [Davis et al., 1990, Stroncek et al., 1991] have suggested that decreasing 
the amount of DMSO will reduce the incidence of these and other side ef-
fects. The total DMSO dose reinfused into patients is generally restricted to 
no more than lg DMSO/Kg/day [Bostrom and Burger, 1999]. The modified 
washing protocol is an effective method of reducing DMSO volume and hence 
enables increased reinfusion volume of cryopreserved cells to be tolerated. 
2.5 Summary 
This chapter has modified the NYCBB HSC washing proto-
col [Rubinstein et al., 1995] by improving the separation of cell pellet 
and supernatant and subsequently validated this change in methodology. In 
line with the original report, this study found improved cell viability and 
no loss of nucleated cells or CFU-GM numbers. Furthermore, there was no 
loss of CD34+HSC and the reduction in free haemoglobin levels indicated 
the removal of cellular lysis products and, indirectly, DMSO. In addition, 
analysis of the effect of washing on these parameters over an extended time 
frame found that the modified washing protocol removed red cell lysates 
and DMSO without affecting the HSC numbers or engraftment potential. 
Therefore, the laboratory data indicates that this procedure would be 
suitable for use in the patient setting. This protocol could also be used 
in the laboratory in the event of delays in reinfusing HSC post-thawing in 
order to improve cell viability and to slow the gradual loss of HSC numbers 
and clonogenic potential over time. 
The modified HSC washing protocol is a feasible practice that reduces the 
morbidity associated with the reinfusion of cryopreserved stem cells without 
adversely affecting HSCs. A clinical trial will be necessary prior to systemic 
adoption of the washing protocol to determine if the procedure is of significant 
benefit to patients. 
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Chapter 3 
Clinical Trial 
3.1 Introduction 
The aim of this thesis was to investigate if washing of thawed stem cell prod-
ucts prior to reinfusion significantly reduces the morbidity associated with 
this procedure. This clinical trial used the modified version of NYCBB's 
washing protocol (Rubinstein et al. 1995) which had beenpreviously vali-
dated in a laboratory study. This was a non-randomised trial to assess the 
side effects experienced by patients undergoing ASCT at the Royal Hobart 
Hospital, as well as the reactions of both their carer and attending nurse, 
using VASQOL surveys. 
We believe that washing of thawed HSC prior to reinfusion will reduce the 
side effects experienced by patients, carers and nurses. Therefore a formal 
clinical trial was required to properly study whether this proposed change in 
clinical practice was of actual value to those individuals involved. Hence, the 
need for a clinical trial of this procedure in the patient setting, studying the 
impact of the washing procedure on patients receiving ASCT, in comparison 
to current practice. 
For the purpose of this thesis it was necessary to use a QOL survey to gain 
information regarding side effects associated with ASCT from the perspective 
of individuals involved. We decided to use a modified version of a VASQOL 
survey previously developed by Rowley 1999 to assess impact of post-thaw 
washing of symptoms associated with ASCT including nausea, pain, flushing, 
nervousness, shortness of breath, unusual smells and tastes. 
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I Reagents 
0.9 3 Saline Infusion BP 
203 Human Serum Albumin (HSA) 
Gentran 40 Dextran 40 Intravenous Infusion 
BP 103 w/v in NaCl 
Intravenous Infusion BP 0.9 w/v 
Table 3.1: Reagents and Suppliers 
I Disposables 
60 ml syringe with Luer lock 
18 G Drawing up needle, non-bevelled 
lOOOml Fenwal Transfer pack container with coupler 
600ml Fenwal Transfer pack container with coupler 
Sampling site coupler 
Hemastix 
Reinfusion line IV set non filtered 
Bactec Peds Plus/F aerobic 
Bactec Plus+ Anaerobic/F 
Suppliers I 
Baxter 
CSL Ltd 
Baxter 
Manufacturers 
Terumo 
Braun 
Baxter 
Baxter 
Fenwal 
Bayer 
Portland Surgical 
BD 
Table 3.2: Disposables and Manufacturers 
I Equipment 
400 Cyclic Fridge 
Class II Biological Safety Cabinet 
PB 3000 Scales 
Plasma Extractor 
RF Sealer Model 2101 
Varifuge 3.0RS 
Tubing Welder 
Water bath 
Manufacturers 
Kelvinator 
Gelman Sciences Australia 
Mettler 
Fenwal 
Se bra 
Heraeus Instruments 
Terumo 
Haake 
Table 3.3: Equipment and Manufacturers 
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3.2 Materials and Methods 
3.2.1 Maintenance of Sterility 
Sterility was maintained with a Class II Biological Safety Cabinet where 
appropriate. 
3.2.2 Solutions 
Isotonic Diluent Solution 
Gent ran 
Saline 
RSA 
500 ml 
400 ml 
100 ml 
Components were mixed and stored at 4 °C. 
3.2.3 Study Samples 
Ethical Approval 
Approval for this study was obtained from the Royal Hobart Hospital Human 
Research Ethics Committee (Project No. H6737). 
Selection of the Study Samples 
All patients undergoing ASCT at the Royal Hobart Hospital were eligible 
for this study and hence all were asked to undertake the VASQOL survey. 
Patients who had a second transplant dose remaining in storage with a mini-
mum CD34 count of 2 x 106 /kg were invited to participate in the Test Arm of 
the trial and hence receive Washed stem cells i.e. patients required 2 trans-
plants, each with a CD34 count of at least of 2 x 106 /kg, to be considered 
eligible for the Test Arm. Patients who declined to participate in the Test 
Arm received Unwashed cells (as per current practice). 
Patients who had only a single transplant dose available were invited to 
undertake the VASQOL survey as a member of the Control Arm. These 
patients received Unwashed stem cells as per current practice. Additionally, 
patients who declined to participate in the Test Arm were invited to join the 
Control Arm. 
Those patients who do not consent to completing the VASQOL survey 
were excluded from the trial as were patients who had a total transplant 
dose of less than 50mL (as these patients do not suffer sufficient side effects 
to warrant reduction by washing). These patients received Unwashed stem 
cells as per usual practice. 
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Sample Size 
The main concern with QOL studies is whether or not there is sufficient 
power in the trial to answer the hypothesis. An Associate Investigator on 
this project, Dr. Simon Wotherspoon, performed power analysis to deter-
mine approximately how many subjects are needed in each arm to obtain 
measurable differences between the two groups. Power analysis using re-
peated measurements requires care as the power of the test is dependent not 
only upon the variability of observations, but also the level of the correlation 
amongst the repeated measurements. In order to obtain sufficient power for 
statistical analysis, it was recommended to employ 20 subjects per arm. 
3.2.4 Experimental Design 
During the four year course of the clinical trial 43 patients enrolled in the 
Unwashed control arm and 19 patients enrolled in the Washed test arm. On 
the day of reinfusion, prior to the administration of pre-medication, nursing 
staff recorded baseline clinical observations on the reinfusion nursing docu-
mentation record (Figure 3.1), including the free haemoglobin level of urine. 
After the administration of pre-medication, the nursing staff repeated all 
clinical observations and documented them on the reinfusion nursing record. 
At this time the patients, their carers and nurses were asked to complete 
their Pre-Reinfusion VASQOL surveys. 
Using the post thaw washing method (previously validated in the labora-
tory phase of this study), the frozen cryobags containing stem cell collections 
of patients enrolled in the Washed test arm were rapidly thawed in a water-
bath at 37 °C. Using aseptic techniques, the bags were spiked with a blood 
pack adaptor and an equal volume of freshly prepared sterile isotonic diluent 
(5% dextran, 2.0% HSA in saline) was slowly added to the cryobag, with con-
stant mixing, and the diluted cells transferred into a 600ml Baxter Fenwal 4R 
2024 bag suitable for centrifuging, at 1400g for 10 minutes to pellet the cells. 
The supernatant, consisting of the DMSO cryopreservative and toxic cell 
lysis products, was removed by manual plasma expression and the cells re-
suspended in fresh dextran/saline to the original volume. The Washed HSCs 
were then transported to the patient bedside and immediately reinfused into 
the patient approximately 35 minutes after thawing had commenced. 
In the event that multiple cryobags were requested for reinfusion, a max-
imum of two bags would be thawed simultaneously in the laboratory by two 
scientists, diluted with isotonic diluent solution and then combined into one 
bag for centrifugation and further processing. The thawing of additional bags 
- would only commence once the reinfusion of previous washed HSC had been 
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Figure 3.1 
REINFUSION NURSING DOCUMENTATION RECORD 
Patient Name: 
--------------~ 
Time of Reinfusion: ______ _ 
Patient: Ur.No:-------------- Date of Reinfusion: 
-------
Volume Reinfused: mls 
=None 1=Mild =Moderate -Life Threatening 
.. - --- . ----- -----.----- --- ----··- ·-· ---- .-- - ····--·-·· -····.-------- . -- -- ··-- ----- -- . ---· - - ···..------- -··-- -- ··-- ----· --------···· .... ·---- _., .. ____ ---·-·-··-· _____ .,_ -- ··----d • 
Event Time T p R BP IPain/ CNS Cough Rash/ Chills Nausea Vomiting Diarrhoea Urine Flushing 
Location Hemastix Test 
!Baseline 
!Post 
l>re-Med 
End ofReinfusion 
successfully completed. 
The frozen cryobags of the patients enrolled in the Unwashed arm of the 
trial were thawed at the bedside in a 37C waterbath immediately prior to 
reinfusion. 
On completion of the reinfusion patients, their carers and nurses were 
asked to complete the Post-Reinfusion VASQOL survey. Nursing staff re-
peated all clinical observations at regular intervals until 6 hours post reinfu-
sion (if reinfusion occured as an in-patient procedure) or at time of discharge 
(if reinfusion was an out-patient procedure). Twenty-four hours post rein-
fusion the patients, their carers and nurses were asked to complete the final 
VASQOL survey. All data collected from VASQOL surveys from the test 
and control arm was assigned a non-identifying collection number, which 
was used for all analysis. 
Microbiological testing was also performed on the expressed supernatant 
of all Washed HSCs to assess the potential for contamination as a result of 
the post-thaw washing. 
VASQOL survey 
The toxicity of the ASCT was measured using a lOcm straight line where 
each end represents the extreme limits of the symptom ie 'no nausea' on one 
end to 'worst possible nausea' on the opposite end (Figure 3.2). The sub-
ject was asked to place a mark along the line to indicate their experience of 
the symptom [Gaston-Johansson et al., 1992]. We also extended the subject 
group in comparison to [Rowley et al., 1999a], to include side effects experi-
enced by family members ("carers") (Figure 3.3) and nursing staff (Figure 
3.4) as a consequence of contact with DMS exhaled by the patient as they 
metabolised DMSO. Furthermore, in contrast to Rowley 1999, no changes 
were made to the medications administrated to patients prior to ASCT. 
Patients and those individuals in close contact with the patient such as 
family members and nursing staff were asked to complete a series of surveys 
to assess the impact of the washing protocol on their own well being. 
Statistical Methods 
The VASQOL responses along the 10 cm line were measured with a ruler 
with the beginning of the line equalling 0 and the data recorded in centrime-
tres. A number of statistical methods to analyse the data obtained from the 
VASQOL surveys. In order to correct for the skewed nature of the data, 
all the data (with the exception of the Wilcoxon rank sum test) underwent 
logarithmic transformation prior to analysis. Wilcoxon rank sum tests and 
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Figure 3.2 
STEM CELL TRANSPLANT PATIENT SURVEY: 
Patient Name: 
--------
UR.No:~--------~ 
DOB: 
PRE-REINFUSION 
Date: _____ _ 
Time: ______ a.m./p.m. 
Please mark the line at the point that describes how you personally feel at this moment 
1. NERVOUSNESS 
Not at all 
2. FLUSHING 
No flushing 
3. NAUSEA 
No nausea 
3. UNUSUAL TASTES 
Normal 
for me 
4. SHORTNESS OF BREATH 
No 
shortness of 
breath. 
5. PAIN 
No pain 
Location of pain: 
Comments: 
Extremely 
The worst 
flushing I can 
im?gine 
The worst 
nausea I 
can imagine 
The worst 
taste I can 
imagine 
The worst 
shortness of 
breath I can 
imagine 
The worst 
pain I can 
imagine 
Figure 3.3 
STEM CELL TRANSPLANT FAMILY MEMBER SURVEY: 
PRE-REINFUSION 
Name: ~------------ Date: -------
Ti me: ______ a.m./p.m. 
Please mark the line at the point that describes how you personally feel at this moment 
1. UNUSUAL SMELLS 
Not at all 
2. NAUSEA 
No nausea 
3. UNUSUAL TASTES 
Normal 
for me 
4. SHORTNESS OF BREATH 
No 
shortness of 
breath. 
5. PAIN 
No pain 
Location of pain: 
Comments: 
Extremely 
unpleasant 
The worst 
nausea I 
can imagine 
The worst 
taste I can 
imagine 
The worst 
shortness of 
breath I can 
imagine 
The worst 
pain I can 
imagine 
Figure 3.4 
STEM CELL TRANSPLANT NURSES SUR~: 
PRE REINFUSION 
Name: ~~~-~~~--~-~-~ Date: ______ _ 
Time: ______ a.m./p.m. 
Please mark the line at the point that describes how you personally feel at this moment 
1. UNUSUAL SMELLS 
Not at all 
2. NAUSEA 
No nausea 
3. UNUSUAL TASTES 
Normal 
for me 
4. SHORTNESS OF BREATH 
No 
shortness of 
breath. 
5. PAIN 
No pain 
Location of pain: 
Comments: 
Extremely 
unpleasant 
The worst 
nausea I 
can imagine 
The worst 
taste I can 
imagine 
The worst 
shortness of 
breath I can 
imagine 
The worst 
pain I can 
imagine 
Welch two sample t-tests were used to compare individual responses across 
treatment groups at the 24 hour mark [Zar, 1999]. A multivariate anal-
ysis of variance (MANOVA) using Wilk's lambda as a test statistic was 
used to compare responses from the two treatment groups at the 24 hour 
mark [Stevens, 2001]. Furthermore, the multivariate approach to repeated 
measures analysis was used to compare the profile of individual responses 
over time [Stevens, 2001]. Figure 3.5 demonstrates a summary of the strat-
egy used for statistical analysis of the VASQOL data and highlights the find-
ings. The criterion for significance was that a probability value of P < 0.1 
indicated weak evidence, a probability value of P < 0.05 indicated moderate 
evidence while a probability value of P < 0.01 indicated strong evidence. 
3.3 Results 
3.3.1 Clinical Details of Patients 
Temperature, blood pressure and urinary haemoglobin for all patients en-
rolled in the clinical trial were measured by nursing staff prior to and post 
ASCT. This was done in order to assess the impact of the washing protocol 
on patient clinical responses in comparison to our current practice. 
Patient Temperature 
Temperature readings measured prior to and post ASCT for patients enrolled 
in the clinical trial are shown in detail in Appendix A. Student's paired t-test 
analysis of the temperature readings demonstrated no significant difference in 
temperature for patients receiving Washed (p = 0.216, n = 14) or Unwashed 
(p = 0.530, n = 31)ASCT as displayed in Figure 3.6. This suggests that 
the results for the Washed group are consistent with the results of those 
patients receiving Unwashed HSC. Therefore, the washing protocol does not 
have an adverse affect on patient temperature and the results are comparable 
to current ASCT practise. 
Patient Systolic Blood Pressure 
Systolic blood pressure is measured during the period of ventricular con-
traction (systole) and is the higher of the two blood pressure readings. 
A systolic blood pressure between 90-120mmHg is defined as "normal" 
while hypertension is usually diagnosed on with a reading of 140mmHg or 
above [Anderson, 2002]. The blood pressure readings taken prior to and 
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Multivariate 
An•r 
Nurses Smell P=-0.030 
Patlent Taste P: 0.049 
Figure 3.5 
QOL Data 
Wilcoxon Welch 
Yes 
l 
5 Main Responses 
Nurses & Carers:Smell 
Patients: Taste, Na11sea, 
Flushing 
No___.: Remaining 
QOL Data 
'o>'ec '- "<'""'7.-,-_,--ce_ -. ,~~'~'""°>"'~- • ,__ :,.; 
MAN OVA 
l 
5 Main Patient 
Responses ~ Taste, Nausea, ~ Flush Ing P=0.014 
' P=0.002 
•:.~-::;7~~~~~~~~r.~.-
• ";;,"'"2~"'"~"7~~~~ .... ;:::;.:;-~~~r 
Figure 3.5: Summary of Statistical Analysis of VASQOL Data. 
Flow chart summary of statistical analysis of VASQOL data obtained at 24 hour time 
point for patients, nurses and carers. 
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Figure 3.6 
Unwashed 
Pre Reinfusion Post Reinfusion 
Washed 
?¥2?::3 
._----=....-,t, 
Pre Reinfusion Post Reinfusion 
Figure 3.6:Comparison of Temperature of Patients Receiving 
Washed and Unwashed ASCT 
Pre and Post ASCT patient temperatures are displayed for Washed and Unwashed 
ASCT as measured by nursing staff. There was no significant difference post reinfusion 
for patients receiving Unwashed ASCT post reinfusion (p = 0.530, n = 31) or Washed 
ASCT (p = 0.216, n = 14) for the patients receiving Washed ASCT. 
post ASCT for patients enrolled in the clinical trial are shown in detail in 
Appendix A. 
Student's paired t-test analysis of the systolic blood pressure readings 
demonstrated a significant difference between pre (range 97-161) and post 
(range 103-166) systolic blood pressure for patients receiving Unwashed 
(p = 0.001) (n = 37) ASCT as displayed in Figure 3.7. However, there was 
no significant difference between pre (range 101-135), and post reinfusion 
(range 102-136) (n = 12) for those patients receiving Washed (p = 0.428) 
ASCT. Therefore, the washing protocol is an advancement on current ASCT 
practice which demonstrated a significant relationship between the reinfusion 
of Unwashed ASCT and increased blood pressure. 
However, if we examine the numbers of subjects that show an increase in 
the groups: 
Increase No Increase 
Washed 25 12 
Unwashed 7 5 
we observe that a greater fraction show an increase in the Unwashed group 
and a Fishers exact test shows no evidence (p= 0.73) of an association be-
tween treatment and BP increase. This may simply be a reflection of the 
lesser power of the Fisher exact test (alternatively contingency table analy-
sis). 
Patient Urinary Haemoglobin 
Dipstick analysis (Hemastix, Bayer) was performed on patient urine obtained 
prior to and post ASCT, in order to measure free haemoglobin and the results 
(in red cell equivalent/ µL) read after 60 seconds. Categories were assigned to 
haemoglobin levels as indicated in Appendix A on the basis of the presence 
(positive = 1) or absence (negative= 0) of urinary haemoglobin. 
The percentage of patients who tested positive for urinary haemoglobin 
post reinfusion was 10.03 (1/10) for the Washed group compared to 27.63 
(8/29) for Unwashed ASCT group. However, if the patients who tested 
positive for urinary haemoglobin prior to ASCT are excluded from analysis 
of the Unwashed ASCT group (4/24) this decreases to 16.73 as displayed in 
Figure 3.8. Thus, the washing protocol does not appear to have an adverse 
effect on patients in comparison to the Unwashed group, and may reduce the 
amount of free haemoglobin excreted by ASCT patients. 
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Figure 3.7 
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Figy,re 3. 7:Comparison of Systolic Blood Pressure of Patients Receiving 
Washed and Unwashed ASCT 
Pre and Post ASCT patient systolic blood pressures are displayed for Washed and 
Unwashed ASCT as measured by nursing staff. There is a significant difference post 
reinfusion for patients receiving Unwashed ASCT post reinfusion (p = 0.001, n = 37), 
whereas there was no difference post reinfusion (p = 0.428, n = 12) for the patients 
receiving Washed ASCT. 
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Figure 3.8:Comparison o[the Post ASCT Urinary Haemoglobin Percentage Results of 
Patients Receiving Washed and Unwashed ASCT 
Patient urinary haemoglobin was measured using a dipstick test post ASCT by nursing 
staff and results were recorded as positive or negative. Results shown for Unwashed are 
of 24 patients and Washed are for 10 patients expressed as percentage of subject group. 
I Patient No. Microbiology 
1 No Growth 
2 Positive Growth1 
3 No Growth 
4 Positive Growth1 
5 No Growth 
6 No Growth 
7 No Growth 
8 No Growth 
9 No Growth 
10 No Growth 
11 No Growth 
12 No Growth 
13 No Growth 
14 No Growth 
15 No Growth 
16 No Growth 
17 No Growth 
18 No Growth 
19 No Growth 
Table 3.4: Washed HSC Microbiology Results 
3.3.2 Microbiology Testing 
Samples for anaerobic (Bactec Plus+) and aerobic (Bactec Peds Plus/F aer-
obic) microbiological testing were taken from the expressed supernatant of 
all patients undergoing reinfusion with Washed HSC as displayed in Table 
3.4. 
As the only two positive bacterial growth reports were from cryobags 
which had been damaged during storage in liquid nitrogen, it is possible that 
these cryobags may have been exposed to contamination prior to post-thaw 
washing. Furthermore, as 89.53 of the samples tested (17 /19) reported no 
growth it appears that possibility of microbiological contamination of the 
HSC as a result of the washing protocol is limited. Therefore, the testing of 
supernatant is a useful quality control measure that validates the safety of 
the washing protocol in relation to bacterial contamination. The decision to 
use damaged cryobags in preference to undamaged bags remaining in storage 
was made by the consulting physician on the basis of HSC dosage. 
1 Patient cryobags damaged during storage in liquid nitrogen. 
50 
Ave. 
SD 
Median 
Ave. 
SD 
Median 
Ave. 
SD 
Median 
Ave 
SD 
Median 
Ave. 
SD 
Median 
Table 3.5 
Unw~shed Patient QOL Summary 
Pre Reinfusion 
!Flushing Unusual Nausea l$.O.B Pain Nervousness 
Tastes 
0.5 1.3 2.3 0.4 0.5 2.7 
1.4 12.2 3.1 1.0 1.3 12.6 
0.0 0.0 0.5 0.0 0.0 12.1 
Post Reinfusion 
iFlushing Unusual Nausea S.O.B Pain Nervousness 
Tastes 
1.1 ~.7 1.4 0.5 0.7 1.6 
12.1 3.0 2.5 1.3 1.8 12.8 
0.0 1.9 0.0 IO.O 0.0 o.o 
At Time of Discharge (or 6 Hours Post Reinfusion) 
Flushing Unusual Nausea S.O.B Pain IN ervousness 
Tastes 
0.4 ~.o 1.9 0.7 0.5 P.6 
0.9 12.2 2.5 1.5 1.0 1.2 
0.0 1.5 0.7 0.0 0.0 0.0 
24 Hours Post Reinfusion 
Flushing Unusual Nausea S.O.B Pain Nervousness 
Tastes 
0.2 2.7 3.4 0.8 0.9 ~.9 
0.4 2.9 3.0 1.5 1.7 1.8 
0.0 2.3 3.1 0.0 0.0 o.o 
!Volume (mls) 
148.6 
100.7 
94.0 
Ave. 
SD 
Median 
Ave. 
SD 
Median 
Ave. 
SD 
Median 
Ave 
SD 
Median 
Ave. 
SD 
Median 
Flushing 
0.7 
1.6 
0.0 
Flushing 
1.1 
1.5 
0.4 
Table 3.6 
Washed Patient QOL Summary 
Pre Reinfusion 
Unusual Nausea S.O.B Pain 
Tastes 
0.9 1.8 J.3 0.6 
1.2 1.8 J.5 1.5 
0.3 1.4 0.0 0.0 
Post Reinfusion 
Unusual Nausea S.O.B Pain 
Tastes 
1.3 1.3 0.3 0.7 
2.1 2.1 0.5 1.0 
0.6 0.3 0.0 0.0 
!Nervousness 
1.0 
1.1 
1.0 
Nervousness 
0.4 
17 
ll 
At Time of Discharge (or 6 Hours Post Reinfusion) 
Flushing !Unusual Nausea S.O.B Pain Nervousness 
Tastes 
1.1 1.1 1.9 14 0.9 0.2 
1.6 1.2 2.5 0.5 1.4 0.4 
0.2 0.7 0.7 0.2 0.4 0.0 
24 Hours Post Reinfusion 
Flushing Unusual Nausea S.O.B Pain · Nervousness 
Tastes 
0.7 0.9 2.1 0.6 0.7 13 
0.9 1.2 2.3 1.0 1.4 J.5 
0.2 0.5 1.7 J.O 0.0 lO 
IVolume{mls) 
116.8 
58.0 
97.0 
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Figure 3.9: Comparison o{Average VASQOL Scores of Symptoms Experienced by 
Patients Receiving Washed and Unwashed ASCT 
V ASQOL scores for symptoms associated with ASCT were assigned over a 24 hour 
period by patients receiving Washed and Unwashed ASCT. Results shown for Un-
washed are of 43 patients and Washed are for 19 patients. 
3.3.3 VASQOL surveys 
Prior to statistical analysis a preliminary analysis of the raw VASQOL data 
for patients, carers and nurses at each time point in the 24 hour period (shown 
in detail in Appendix B) was performed in order to determine if there were 
any trends in the observations for flushing, tastes, nausea, smells, shortness 
of breath, pain and nervousness. All average VASQOL results of less than 
1.0 were excluded from further exploratory comment given the proximity of 
these values to zero on the VASQOL lOcm linear scale which signifies no 
response therefore subjects didn't exhibit these symptoms. The findings of 
the preliminary analysis provided guidance for the more detailed statistical 
analysis of all the VASQOL data. 
Exploratory Analysis 
Examination of the average VASQOL data at each time point over the 24 
hour period suggests that regardless of whether individuals were involved 
with Unwashed or Washed HSC that the patients (Tables 3.5 and 3.6) nurses 
(Tables 3.7 and 3.8)and carers (Tables 3.9 and 3.10) did not routinely ex-
perience shortness of breath and pain following ASCT. Additionally, nausea 
and unusual tastes were not regularly reported by nurses and carers following 
ASCT. Therefore these symptoms may only an occasional issue for individ-
uals involved with ASCT. 
Patients who received Unwashed HSC recorded an average VASQOL of 
1.1 (SD 2.1) for flushing post reinfusion, however this declines to below 1.0 for 
subsequent readings (Table 3.5). These results are comparable with Washed 
ASCT patients (Table 3.6). As the average VASQOL values for both the 
Unwashed and Washed groups are close to the cut off value throughout the 
24 hour period, flushing appears to be only a minor issue to patients following 
ASCT (Figure 3.9). 
The average VASQOL scores for unusual tastes remain above 1.0 for Un-
washed patients throughout the survey period suggesting that this symptom 
is a concern for patients receiving Unwashed RSC (Table 3.5, Figure 3.9). 
In comparison, the average VASQOL values for the Washed patient group 
are close to the cut off value throughout the 24 hour period nausea Table 
3. 6) (Figure 3. 9). This suggests that unusual tastes are a lesser concern for 
those patients who received Washed HSC and is an improvement on current 
ASCT practise. 
Nausea following ASCT is a concern for patients with average VASQOL 
values remaining above 1.0 for both the Unwashed and Washed patient 
groups throughout the 24 hour period (Tables 3.5 and 3.6) (Figure 3.9). 
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However, it is worth noting that the average pre reinfusion VASQOL values 
for nausea were greater than 1.0 for both the Unwashed and Washed groups 
(2.3 SD3.1 and 1.8 SD 1.8 respectively). 
The only symptom to receive average VASQOL values of greater than 
1.0 following reinfusion (as observed by nurses involved in Unwashed ASCT) 
was unusual smells (Table 3.7). However, by the 24 hour tim~ point the 
average VASQOL value had decreased by approximately 503 to 1.1 (SD2.2) 
suggesting that the intensity of the smell was diminishing as the DMSO was 
excreted by the patients (Figure 3.10). Nurses involved in Washed ASCT 
also recorded average VASQOL values of greater than 1.0 post reinfusion 
which decreased over time (Table 3.8). By the 24 hour time point the av-
erage VASQOL score had decreased to 0.0 (SDO.l). This suggests that the 
intensity of the smell associated with Washed ASCT diminished at a faster 
rate than experienced by nurses associated with Unwashed ASCT. 
Similar to the nurses, unusual smells was also the only symptom observed 
by carers involved to receive average VASQOL values of greater than 1.0 
at all time points post reinfusion for Unwashed ASCT (Table 3.9 ). This 
suggests that unusual smells remain a concern for carers throughout the 
24 hour period following Unwashed ASCT. Carers associated with Washed 
ASCTs reported average VASQOL values of 1.8 (SDl.5) and 2.5 (SD2.4) at 
the post reinfusion and 6 hours time points. However, by the 24 hour time 
point the average VASQOL had decreased to 0.3 suggesting that the smell 
was no longer a concern to carers which is in contrast to the experience of 
carers associated with Unwashed ASCT (Figure 3.11). 
The average volume reinfused in the Washed arm was 116.8mls (SD 58.0) 
(Table 3.6), while the average volume reinfused in the Unwashed arm of 
the clinical trial were 148.6 mls (SD 100.7) (Table 3.5). However, as the 
median volumes received by patients in the Unwashed arm of the clinical 
trial was 94.0 mls (Table 3.5) and 97.0 mls (Table 3.6) for patients enrolled 
in the Washed arm are comparable, this suggests that the differences in 
average volumes reinfused is due to a few larger volume reinfusions rather 
than consistent differences in volumes (see Appendix B) between the Washed 
and Unwashed arms. 
Statistical analysis 
Preliminary analysis of the VASQOL responses for symptoms previously at-
tributed to ASCT [Rowley et al., 1999a] suggests that unusual tastes, nausea 
and flushing seem to be of most concern for patients, while unusual smells 
were the main concern for nurses and carers therefore they will be the primary 
focus of the statistical analysis. 
52 
Table 3.7 
Unwashed Nurses QOL Summary 
Pre Reinfusion 
Smells Unusual Nausea S.O.B Pain 
Tastes 
Ave. 0.1 0.0 0.1 0.0 0.1 
SD 0.5 0.0 0.5 0.1 0.4 
Median 0.0 0.0 0.0 0.0 0.0 
Post Reinfusion 
Smells Unusual Nausea S.O.B Pain 
Tastes 
Ave. 2.2 0.3 0.3 0.0 0.1 
SD 1.7 0.8 0.7 0.1 0.2 
Median 1.8 0.0 0.0 0.0 0.0 
At Time of Discharge (or 6 Hours Post Reinfusion) 
Smells Unusual Nausea S.O.B Pain 
Tastes 
Ave. 2.3 0.4 0.1 0.2 0.1 
SD 2.5 1.7 0.6 0.9 0.3 
Median 1.7 0.0 0.0 0.0 0.0 
24 Hours Post Reinfusion 
Smells Unusual Nausea S.O.B Pain 
Tastes 
Ave. 1.1 0.1 0.1 0.0 0.0 
SD 2.2 0.3 0.2 0.2 0.1 
Median 0.0 0.0 0.0 0.0 0.0 
Ave. 
SD 
Median 
Ave. 
SD 
Median 
Table 3.8 
Washed Nurse QOL Summary 
Pre Reinfusion 
Smells , !Unusual Nausea S.O.B Pain 
Tastes 
0.1 0.0 0.0 0.0 0.1 
0.3 0.1 0.1 ).1 0.3 
0.0 0.0 0.0 ).0 0.0 
Post Reinfusion 
Smells Unusual !Nausea s.o.B !Pain 
Tastes 
2.2 0.0 0.1 0.0 0.1 
2.8 0.1 0.2 0.1 0.3 
1.1 0.0 0.0 0.0 0.0 
, 
At Time of Discharge (or 6 Hours Post Reinfusion) 
Smells Unusual Nausea s.o.B Pain 
Tastes 
Ave. 1.3 0.1 0.0 0.0 0.2 
SD 1.9 0.2 0.1 0.2 0.3 
Median 0.1 0.2 0.1 0.1 0.2 
24 Hours Post Reinfusion 
Smells Unusual Nausea S.O.B Pain 
Tastes 
Ave. 0.0 0.0 0.0 0.0 0.2 
SD 0.1 0.1 0.0 0.1 0.5 
Median 0.0 0.0 0.0 0.0 0.0 
Figure 3.10 
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Figure 3.10: Comparison ofAverage VASQOL Scores of Unusual Smells Experienced 
by Nurses Exposed to Washed and Unwashed ASCT 
V ASQOL scores for unusual smells associated with ASCT were assigned over a 24 hour 
period by nurses to exposed to Washed and Unwashed ASCT. Results shown for Un-
washed are of 43 nurses and Washed are for 16 nurses. 
Table 3.9 
Unwashed Carer QOL Summary 
Pre Reinfusion 
Smells Unusual Nausea S.O.B 
Tastes 
Ave. 0.0 0.1 0.4 0.1 
SD 0.0 0.3 1.0 0.1 
Median 0.0 0.0 0.0 0.0 
Post Reinfusion 
Smells Unusual Nausea S.O.B 
Tastes 
Ave. 2.2 0.3 0.3 0.1 
SD 3.0 1.0 1.0 0.1 
Median 0.7 0.0 0.0 0.0 
Pain 
0.0 
0.1 
0.0 
Pain 
0.0 
0.1 
0.0 
At Time of Discharge (or 6 Hours Post Reinfusion) 
Smells Unusual Nausea S.0.B Pain 
Tastes 
Ave. 3.9 0.0 1.4 0.1 0.0 
SD 3.5 1.5 2.1 0.2 0.1 
Median 2.4 0.0 0.0 0.0 0.0 
24 Hours Post Reinfusion 
Smells Unusual Nausea S.O.B Pain 
Tastes 
Ave. 2.7 0.1 0.1 0.1 0.1 
SD 3.4 0.2 0.3 0.3 0.2 
Median 1.2 0.0 0.0 0.0 0.0 
Ave. 
SD 
Median 
Ave. 
SD 
Median 
Table 3.10 
Washed Carer QOL Summary 
Pre Reinfusion 
Smells Unusual !Nausea S.O.B Pain 
Tastes 
0.2 0.0 0.2 0.1 0.0 
0.7 0.2 0.7 J.2 0.1 
0.0 0.0 0.0 lO 0.0 
Post Reinfusion 
Smells Unusual [Nausea S.O.B !Pain 
Tastes 
1.8 0.2 0.0 0.1 KU 
1.5 0.7 0.1 0.2 0.3 
1.7 0.0 0.0 0.0 0.0 
At Time of Discharge (or 6 Hours Post Reinfusion) 
Smells [Unusual !Nausea s.o.B Pain 
Tastes 
Ave. 2.5 0.1 0.4 0.1 J.1 
SD 2.4 0.1 1.0 0.2 0.2 
Median 1.8 0.0 0.0 0.0 0.0 
24 Hours Post Reinfusion 
Smells !Unusual Nausea S.O.B Pain 
Tastes 
Ave. 0.3 0.2 0.2 0.2 0.1 
SD 0.6 0.4 0.5 0.5 0.2 
Median 0.0 0.0 J.O 0.0 0.0 
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Figure 3.11: Comparison of Average VASQOL Score of Unusual Smells Experienced by 
Carers Exposed to Washed and Unwashed ASCT 
V ASQOL scores for unusual smells associated with ASCT were assigned over a 24 
hour period by carers to exposed to Washed and Unwashed ASCT. Results shown for 
Unwashed are of 26 carers and Washed are for 17 carers. 
Table 3.11 Comparison of p Values of VASQOL Responses for Washed and 
Unwashed Groups at 24 hour time point 
Carers Nurses Patients 
Symptom Welch Wilcoxon Welch Wilcoxon Welch Wilcoxon 
Smell 0.021 0.064 0.003 0.059 ... ... 
Taste 0.335 0.513 0.360 0.886 0.062 0.077 
Nausea 0.407 0.415 0.210 0.861 0.072 0.049 
SOB 0.761 0.767 0.878 0.871 0.670 0.931 
Pain 0.703 0.813 0.984 0.871 0.697 0.922 
Flushing ... ... ... .. . 0.047 0.023 
Nervousness ... ... . .. ... 0.095 0.606 
The variability of data obtained from the VASQOL surveys (shown in 
detail in Appendix B) influenced the choice of statistical methods required 
for analysis. Extensive graphical examination showed no indication that par-
ticular nurses were responsible for the observed differences in scores. Many 
of the responses were close to zero, however there were also several extreme 
responses which produce skewed data and increase the overall mean and SD. 
Therefore, with the exception of the Wilcoxon rank sum test, logarithmic 
transformation of the VASQOL data was necessary prior to statistical anal-
ysis to correct for the skewed nature of the data [Azcel, 1999]. 
Recall that the criterion for significance was that a probability value of 
P < 0.1 indicated weak evidence, a probability value of P < 0.05 indicated 
moderate evidence while a probability value of P < 0.01 indicated strong 
evidence. 
Table 3.11 shows the results of the Welch t-tests and the Wilcoxon rank 
sum tests applied to all of the data collected at the 24 hour time point. As 
the majority of our ASCTs are performed as an outpatient procedure, the 
24 hour time point were chosen for statistical analysis as this correlates with 
the first post transplant evaluation of patients following their return in our 
outpatient facility for monitoring. Although the Welch test shows strong 
evidence, the more conservative Wilcoxon test shows moderate evidence of 
a treatment difference between Washed and Unwashed responses for smell 
from both carers (p = 0.021, p = 0.064) and nurses (p = 0.003, p = 0.059) 
perspective. Furthermore, both the tests also support the preliminary anal-
ysis observations of a treatment difference between Washed and Unwashed 
responses for nausea (p = 0.072, p = 0.049), flushing (p = 0.047, p = 0.023) 
and tastes (p = 0.062, p = 0.077) for patients at the 24 hour mark. 
The patient responses relating to nausea, unusual tastes and flushing as 
53 
Table 3.12 Comparison of MANOVA analysis for Washed and Unwashed 
Groups at 24 hour time point 
Carers & Nurses & Patients Patients 
Wilks Lambda I p Value Wilks Lambda I p Value 
I 0.480 1 0.014 1 0.123 1 0.002 
well as responses from nurses and carers relating to unusual smells were of 
primary interest. Shortness of breath, pain and nervousness for all individuals 
as well as taste and nausea for nurses and carers were also analysed for 
completeness which showed no significant differences between the Washed 
and Unwashed groups. Therefore further detailed analysis will be confined 
to smell responses for nurses and carers as well as nausea, flushing and taste 
for patients. 
At the 24 hour point the results of the MANOVA analysis as applied 
to these five responses of interest indicates a significant difference between 
the Washed and Unwashed responses as shown in Table 3.12 (Wilks lambda 
= 0.480 and p = 0.014). However, this analysis requires a complete set 
of data and if any of the responses were missing, as was often the case for 
the smell response from both the nurses and carers, the entire case must be 
deleted from the analysis, reducing the strength of the analysis. Figure 3.12 
shows QQ plots [Stevens, 2001] of the residuals from the fit for both the 
combined responses and of just the patient responses. The QQ plots of the 
residuals from the fit for the combined response suggests that the data is 
not normally distributed and remains skewed even after log transformation 
casting some doubt on the reliability of the MANOVA analysis. 
The results of the same MANOVA analysis restricted to just the three 
responses from the patients at 24 hours displayed in Table 3.12., demonstrates 
that washing has a significant effect on the patient responses (Wilks lambda 
= 0.723 and p = 0.002). Additionally, the QQ plots of just the patient 
responses (Figure 3.12) were improved in comparison, as more data sets 
were used. Therefore, the MANOVA analysis of just the patient responses is 
more reliable and demonstrates a treatment difference between the Washed 
and Unwashed responses, indicating an improvement on the current ASCT 
procedure. 
Multivariate analysis of the 5 main VASQOL responses for all time points 
is outlined in Table 3.13. In this analysis the changes in response over time 
were analysed with a multivariate analysis of variance to establish if there 
was a change ("shift") in the overall group mean as well as if there was any 
differences between the responses over time ("parallelism"). As was the case 
54 
(/) 
(.) 
ti 
,-- -
o-
P. Nausea 
0 00 
or; 
0 
0 
~ 
cs> 
0 
CD 
0 
0 
OOO 
Figure 3.12 
P. Taste 
0 0 
ccoo 
OJ 
OOO 
cs> 
0- Of> 
0 
CXID 
0 
0 
N 
00
C)l_oo 
~~,~~,~---.-,~---.-,~----.-,~ 
0 0 
,_ 
Q.l 
"E 
0 
I I I I I 
-2 -1 0 1 2 -2 -1 0 1 2 
c. Smen N.Smell P. Flushim:i 
0 q_ oo 0 
0 
....: -
q_ 
0 
l{) 
c:i -
I 
0 
·-I 0 0000 
I I 
-2 -1 
I 
0 
ofPO 
0 
0 
0 
I 
1 
0 
I 
2 
q_ 
0 
l{) 
cf - o o ocx::mm 
I I 
-2 -1 
I 
0 
0 
0 
I 
1 
0 
"L 
0 
0 
l{) 
ci -
I 
I 
2 
Expected Normal Order Statistics 
0 
0 
0 
<XDmID 
0 OOO 
I I I I 
-2 -1 0 1 
Figure 3.12: QO Plots of the Five Main Responses for all Subjects at the 24 
Hour Time Point. 
QQ plots ofVASQOL scores from patients for unusual tastes, flushing, nausea 
and unusual smells for both nurses and carers associated with ASCT at the 24 
hour point. 
I 
2 
Table 3.13 Comparison of Multivariate Analysis of VASQOL Responses p 
values for Washed and Unwashed Groups at all time points 
Carers Nurses Patients 
Symptom parallelism mean shift parallelism mean shift parallelism 
Smell 0.280 0.364 0.076 0.030 ... 
Taste ... ... ... ... 0.263 
Nausea ... ... ... ... 0.491 
Flushing ... ... . .. . .. 0.343 
for the MANOVA if any response was missing, then all observations for that 
case were ignored. The majority of the responses do not demonstrate any 
significant difference as a consequence of the washing protocol over time. 
However, there is evidence of a treatment difference for both nurses smells 
(p = 0.030) and patient tastes (p = 0.049) for all time points. This suggests 
that the washing protocol reduced the impact of unusual tastes and smells 
for patients and nurses respectively over the 24 hour time period. 
3 .4 Discussion 
The potential to reduce re-infusional toxicity associated with ASCT by 
the safe post-thaw removal of DMSO and cellular debris has been a pos-
sibility since the NYCBB reported improved recovery of viable cryopre-
served umbilical cord blood HSC following washing with isotonic solu-
tion [Rubinstein et al., 1995]. In addition, the impact of post-thaw washing 
of upon patient recovery has been successfully investigated with regard to 
patient engraftment [Nagamura-Inoue et al., 2003, Syme et al., 2004]. How-
ever, little research has been conducted from the patient perspective in order 
to determine the extent of the reduction in side effects associated with the 
reinfusion of HSC. This thesis reports on the findings of a clinical trial to 
determine if the procedure is of significant benefit to patients. 
The measurement of ASCT patient physical observations pre and post 
reinfusion by nursing staff provides valuable insight into the impact of wash-
ing HSC on patient well-being. This study demonstrated a significant cor-
relation between the reinfusion of Unwashed ASCT and elevated blood 
pressure, which is consistent with previous findings [Kessinger et al., 1990, 
Davis et al., 1990, Stroncek et al., 1991]. Possible causes of hypertension re-
lated to ASCT include the effect of DMSO on cardiovascular or smooth 
muscles as well as the infusion of cell lysis products [Davis et al., 1990]. In 
contrast, the reinfusion of Washed HSC does not have an adverse effect on 
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mean shift 
... 
0.049 
0.243 
0.263 
patient blood pressure. Hence, washing HSC post-thawing reduces a po-
tential cause of hypertension for ASCT patients and the associated compli-
cations including severe headaches, blurred vision, myocardial infarction or 
cerebrovascular accident [Anderson, 2002]. Therefore, it is an improvement 
on the reinfusion of unwashed HSC which has a significant correlation with 
increased blood pressure. 
The washing protocol did not have any effect on patient temperature and 
the results are comparable to current ASCT practise. Moreover, as all of 
the samples from Washed supernatants taken from undamaged cryobags did 
not demonstrate any evidence of bacterial growth, the washing procedure 
does not appear to increase the risk of bacterial contamination. This is an 
important point from a Good Manufacturing Process (GMP) perspective as 
the extra manipulation due to washing does not increase manufacturing risk. 
Testing of urine for free haemoglobin demonstrated a slight reduction 
in the percentage of Washed ASCT patients who tested positive for uri-
nary haemoglobin post reinfusion in comparison to the Unwashed ASCT 
patient group. Haemoglobinuria has often been reported as a possible 
side effect of ASCT [Styler et al., 1992, Rowley et al., 1999a] with one 
previous study reporting that of 100 ASCT patients, 92% experienced 
haemoglobinuria and 80% experienced red urine post reinfusion of cryop-
reserved HSC [Kessinger et al., 1990]. Therefore the comparable results for 
free haemoglobin in our clinical trial of the Unwashed and Washed ASCT 
patient groups suggests that current HSC collection and storage strategies 
have already reduced the amount of red cell lysis products reinfused into 
patients during ASCT. However, in the event of large volume reinfusions, a 
protocol to reduce urinary haemoglobin by approximately 90% as validated 
by the laboratory study, remains an advantage. 
Possible causes for the five patients who tested positive for uri-
nary haemogloblin pre ASCT include damage to the epithelial cells from 
chemotherapy, kidney disease, urinary tract infection, bladder inflammation, 
prostrate gland enlargement, kidney stones or cancer of the prostate, bladder 
or kidneys [Anderson, 2002] [Gertz et al., 2004]. 
A number of problems with VASQOL surveys became apparent during the 
clinical trial including the recruitment of patients, subject compliance in the 
completion and return of surveys as well as analysis of data, all of which have 
been previously documented [Cella and Tulsky, 1993] [Cella, 1996]. There-
fore, a number of strategies were instigated to counter these problems. In 
order to improve recruitment of subjects it was essential to initiate direct con-
tact with the transplant co-ordinator and consultant physicians, informing 
them of all potential candidates for the clinical trial. Furthermore, to im-
prove patient compliance it was necessary to educate all individuals involved 
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(patients, carers, medical consultants and nursing staff) about the VASQOL 
survey and to work in conjunction with the transplant co-ordinator to fol-
lowup all participants in the clinical trial. 
As VASQOL observations are subjective, there is huge variability in re-
sponses between individuals which makes for challenging data analysis. A 
possible strategy to reduce variability between subjects in future studies 
could be the use of a fixed set of observers throughout the VASQOL trial (i.e. 
nurses). Despite these issues, the data obtained from the VASQOL surveys 
provide an invaluable opportunity for subjective evaluation of the symptoms 
associated with the use of Washed and Unwashed RSC in ASCT from the 
perspective of the patients as well as nurses and carers. 
Exploratory analysis of the VASQOL responses for all the symptoms 
previously associated with reinfusion (flushing, nausea, shortness of breath, 
pain, unusual smells and tastes) [Rowley et al., 1999a] suggested that the 
most commonly reported side effect following ASCT for patients was un-
usual tastes, although nausea and flushing were also concerns. In addition, 
unusual smells were the most commonly reported ASCT side effect for both 
the carers and nurses. The average VASQOL scores for the Washed and Un-
washed groups suggested all of those individuals (patients, nurses and carers) 
involved with Washed ASCT experienced a faster rate of recovery from these 
ASCT related side effects. 
As a result of the restrictions of this non-randomised clinical trial, it is 
also possible that any differences between the Washed and Unwashed results 
are related to differences in the sample size and reinfusion volumes of the 
respective treatment groups. However, the results do not demonstrate a clear 
relationship between reinfusion volume and VASQOL response i.e. for every 
large volume reinfusion that triggers a substantial response there is a large 
volume reinfusion that elicits a negligible response (as displayed in Figure 
3.13.). Accordingly, it is likely that reinfusion volume is only one of a number 
of potential variables and that some individuals may be more sensitive to 
ASCT related side effects than others ( e.g patients with a smaller body mass, 
or have experienced recent vomiting or nausea [Synder et al., 2004]). 
As a consequence of the findings of the exploratory analysis, the Wilcoxon 
rank sum and Welch t-test tests were applied to the VASQOL responses of 
patient flushing, nausea and unpleasant tastes, as well as unusual smells as 
reported by carers and nurses at the 24 hour time point. The Welch t-test is a 
test of equality of two population distributions and is useful in testing for the 
equality of two population means. In comparison, the two-sample Wilcoxon 
rank sum test is used when the assumption of normal population distributions 
is not met and is slightly stronger than the Wilcoxon test [Azcel, 1999]. Both 
these tests showed weak to moderate evidence of treatment differences for 
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Figu.re 3.13: VASQOL Scores of Unusual Tastes Experienced by Patients versus 
Volume for Washed and Unwashed ASCTat 6 hour time point. 
V ASQOL scores for unusual tastes associated with ASCT were assigned over a 
24 hour period by patients exposed to Washed and Unwashed ASCT. Results 
shown for Unwashed are of 43 patients and Washed are for 16 patients. 
the patient symptoms of flushing, nausea and taste at the 24 hour time point. 
There is also weak to moderate evidence of treatment difference for smells as 
experienced by carers. Furthermore there is moderate to strong evidence of a 
difference for the smells as experienced by nurses caring for ASCT patients. 
This demonstrates that the washing protocol reduced the impact of a number 
of ASCT related side effects from the point of view of patients, nurses and 
carers. 
As the majority of ASCTs performed at the Royal Hobart Hospital (RHH) 
are conducted on an outpatient basis, we are reliant upon carers monitoring 
the patients in the first phases of the ASCT post reinfusion. A previous 
study of 22 nurses involved with ASCT described the use of odor avoidance 
and distancing strategies that potentially compromised the nurse-patient re-
lationship following ASCT [Prior et al., 2000]. This "distancing strategy" is 
therefore probably applicable to carers as well. Anecdotally, nurses at the 
RHH have reported headaches, migraines as well as nausea in the presence 
of the unpleasant smell generated by ASCT patients in the hours following 
reinfusion of HSC. Hence the washing procedure has the potential to improve 
the working conditions, and thus the delivery of patient care by both nurses 
and carers, by reducing the unpleasant smells associated with ASCT. 
For completeness, the Wilcoxon rank sum and Welch tests were also ap-
plied to the remaining responses for patients, carers and nurses, however, 
there was no significant difference detected for any of this data at the 24 
hour time point. Therefore, secondary analysis to generate potential further 
hypotheses was restricted to these five "main" VASQOL responses (i.e. un-
usual smells for nurses and carers and nausea, flushing and unusual tastes 
for the patients) as there was no evidence that the remaining responses were 
statistically significant. 
Multivariate analysis of variance (MANOVA) is useful in experimental 
situations, where at least some of the independent variables are manipu-
lated [Azcel, 1999]. However, the MANOVA test requires a complete set of 
responses for every case, any case that has a missing response is deleted from 
the analysis. Accordingly, as there were many missing responses from the 
nurses and the carers, only a restricted analysis could be performed on the 
combined data from the five main VASQOL responses which suggested ev-
idence of a treatment difference. The responses were log transformed in an 
attempt to meet the Normality assumption of the MANOVA. However the 
QQ plots of the residuals from the fits suggested that even after log transfor-
mation the responses were not particularly Normally distributed. Therefore, 
although this data supports the findings of a treatment difference as indi-
cated by the the Wilcoxon rank sum and Welch tests, they are unreliable 
and so additional analysis was required. 
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When the MANOVA analysis was restricted to just the patient responses 
of taste, nausea and flushing, since more data sets were included, the findings 
of the restricted analysis were more reliable. These findings demonstrate 
strong evidence that the washing protocol had a significant effect on the 
patient responses at the 24 hour time point, reducing the duration of these 
symptoms in comparison to those patients receiving Unwashed HSCs. 
The changes in response over the 24 hour period following ASCT for the 
five main VASQOL responses were also analysed with a multivariate analysis 
of variance. If any response was missing, then all observations for that case 
were excluded as was the case for the MANOVA test. The majority of the 
responses do not demonstrate any significant difference as a consequence of 
the washing protocol over time. Nevertheless, there is evidence of a treatment 
difference for both nurse smells and patient tastes for all time points. This 
suggests that the washing protocol reduced the impact of unusual tastes and 
smells for patients and nurses, respectively over the 24 hour time period. 
A particular example of where washing of cells prior to ASCT en-
hances patient safety are patients with Amyloid light chain (AL) disease. 
The morbidity and mortality of AL patients undergoing ASCT is higher 
than for patients undergoing ASCT for other haematological malignancies 
[Worel et al., 2006]. A number of symptoms have been reported in AL pa-
tients following ASCT including gastrointestinal complications (including 
bleeding and perforation) as well as arrhythmias in patients with cardiac 
involvement [Worel et al., 2006]. Since DMSO can solubilise amyloid de-
posits in-vitro, the reinfusion of DMSO during the ASCT is an additional 
concern for AL patients with cardiac involvement [Gertz et al., 2004]. Se-
vere respiratory distress also has been reported in a cardiac amyloid patient 
within seconds of a autologous reinfusion [Benekli et al., 2000]. The exact 
mechanism in this case is uncertain as the release of histamine by DMSO or 
from damaged granulocytes has also been reported to cause various degrees 
of AV nodal conduction block [Styler et al., 1992] [Benekli et al., 2000]. As 
a result of the increased risk of reinfusion related toxicities, the washing of 
HSC post-thawing has been recommended in order to reduce the amount of 
DMSO reinfused into cardiac amyloid patients [Benekli et al., 2000]. 
Post-thaw washing of HSC should also be considered as an option for 
extending the viability of HSC in the event of unexpected delays between 
thawing and reinfusion. It is also worth considering for those patients who 
report recent or easily triggered nausea and vomiting, have been heav-
ily conditioned with chemotherapy, or have a smaller body mass ( <70 
kg) [Synder et al., 2004]. There are also numerous advantages for labora-
tory and nursing staff. Although the procedure is time consuming for the 
laboratory staff, once the HSCs have been resuspended post washing, the 
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time taken for reinfusion at the patient bedside is reduced. Thawing HSCs 
in the laboratory provides the opportunity to filter platelet clumps before 
transportation to the ward, therefore removing a cause of delay during rein-
fusion. Reducing the time required for HSC reinfusion on the ward decreases 
the time spent by both nursing and laboratory staff performing the proce-
dure, whilst improving the efficacy safety and quality of patient care. 
3.5 Summary 
This clinical trial provided an invaluable opportunity to assess the impact of 
the washing protocol for HSC prior to reinfusion on ASCT side effects from 
the perspective of patients, nurses and carers. Patient observations pre and 
post ASCT (provided by nursing staff) suggest that there is no adverse effect 
on patient temperature, urinary haemoglobin and blood pressure in those in-
dividuals receiving Washed HSC in comparison to Unwashed. Additionally, 
the washing protocol does not appear to increase the incidence of micro-
biological contamination for undamaged cryobags. Furthermore, the data 
suggests that washing has an significant impact on reducing the incidence of 
increased blood pressure associated with ASCT. 
Statistical analysis of the VASQOL responses demonstrated evidence of 
post-thaw washing of HSC improving several symptoms associated with re-
infusion including flushing, nausea and unpleasant tastes for patients and 
unusual smells for both carers and nurses. This suggests that the washing 
protocol is not only beneficial to patients but also to nursing staff and carers, 
and subsequently may improve their delivery of patient care. 
Consequently, there are a number of circumstances in which a post-
thawing strategy is beneficial for the patients. This washing protocol reduces 
the amount of cellular debris and DMSO reinfused as well as diminishing pa-
tient discomfort and therefore should be considered in the event of large 
volume reinfusions, patient allergies or cardiac issues. 
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Chapter 4 
Discussion 
Autologous haemopoetic stem cell transplantation involves the intravenous 
infusion of the patients own HSCs, collected from BM or PB, to replace dis-
eased BM or to replenish terminally damaged BM after the use of myeloabla-
tive therapy [Armitage, 1994]. Cryoprotectants such as DMSO are therefore 
necessary to protect HSC membrane integrity, and hence survival, by pre-
venting the formation of ice crystals during cryopreservation and subsequent 
storage in liquid nitrogen [Rowley, 1992]. Consequently, when the patient is 
reinfused they receive DMSO, ruptured granulocytes and red cell debris, as 
well as HSC. 
The NYCBB post-thaw washing procedure provides a method for wash-
ing cryopreserved HSC to remove DMSO (and cellular debris) without 
affecting the cell viability or clonogenic ability [Rubinstein et al., 1995]. 
The potential to remove DMSO and cellular debris from cryopre-
served HSC prior to reinfusion provides an opportunity to reduce nu-
merous re-infusional side effects such as nausea, vomiting, flushing 
and increased blood pressure [Davis et al., 1990, Stroncek et al., 1991, 
Rowley et al., 1999b, Hoyt et al., 2000]. This thesis reports on the labora-
tory validation of a modified NYCBB method as well as a clinical trial to 
determine if the procedure is of significant benefit to patients. 
Cell loss remains a concern with the NYCBB protocol with one study re-
porting a median loss of 27.2% (range 11.1 to 41.2%) of total nuclear cells in 
a study of 12 cord bloods [Antonenas et al., 2001]. This thesis has validated 
a modified version of the NYCBB method in which the rate of centrifugation 
was increased from 400 g to 1400 g, in order to improve the separation of 
the supernatant and cellular pellet. The increased centrifuge speed used in 
this investigation resulted in improved separation of cell pellets from super-
natant, however it also increased the risk of cellular damage. As desired, the 
removal of the supernatant (containing DMSO, red cell debris and ruptured 
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granulocytes) by plasma expression was achieved without disturbing the cell 
pellet. The laboratory validation demonstrated that the modified NYCBB 
method did not result in any significant loss of cells while improving overall 
cell viability and reducing the incidence of cell clumping post-thawing. 
Multi parameter testing was used to assess the impact of the post-
thaw washing protocol on HSC. The enumeration of cells expressing CD34 
antigens is the in-vitro standard for assessment of stem cell collections 
engraftment potential, as it provides a rapid indication of HSC num-
bers [Siena et al., 1991, Keeney et al., 1998]. Viable CD34+analysis was 
used to determine the number of HSC present using 7 AAD (a viability 
dye) [Keeney et al., 1998]. The finding of no significant difference in vi-
able CD34+HSC counts between Washed and Unwashed cells demonstrates 
that the increased centrifugal speed does not adversely affect viable HSC 
numbers. Colony Forming Units Granulocyte Macrophage (CFU-GM) as-
says were performed to assess the clonogenic ability of the HSCs to mature 
into macrophages and granulocytes, an indication of the haematopoietic pro-
genitor content of a stem cell collection [Eaves and Lambie, 1995]. 
On the basis of these results, the modified NYCBB protocol does not ad-
versely affect the number of viable CD34+HSC or their clonogenic potential. 
Moreover, the washing protocol appeared to halt the decline in overall cell 
viability observed over time in Unwashed cells while dramatically reducing 
the level of free haemoglobin and, by extrapolation, DMSO from harvests. 
Therefore the increased centrifugation rate has improved separation of the 
cellular pellet and supernatant without damage to the HSCs. 
As a consequence of the laboratory validation phase of this thesis, 
the Flow Cytometry laboratory at the RHH adopted a modification of 
the ISCT guidelines in which a known number of fluorescent micro-
spheres is used to provide an absolute count direct from the flow cytome-
ter [Keeney et al., 1998]. This removed the need for a WCC from an auto-
mated haematology analyser (eliminating a source of potential error), while 
converting the flow cytometer into a single platform CD34 +cell-counting de-
vice. Furthermore, we expanded the single platform method for CD34+cell 
counts by incorporating 7 AAD (a viability dye), to identify viable CD34+ cells 
[Keeney et al., 1998]. This method is also now routinely used in our clinical 
lab for viable CD34+cell counts for post cryopreservation sample analysis. 
A non-randomised clinical trial was conducted in order to determine if 
post-thaw washing of stem cell products prior to reinfusion significantly re-
duces the morbidity associated with this procedure. 
The impact of post-thaw washing of HSC on patient recovery 
has been successfully investigated with regard to patient engraft-
ment [Nagamura-Inoue et al., 2003, Syme et al., 2004]. A modified version 
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of a VASQOL survey previously developed [Rowley et al., 1999a] to assess 
impact of post-thaw washing of symptoms associated with ASCT was used 
in our clinical trial. Symptoms that were monitored over 24 hours follow-
ing ASCT include nausea, pain, flushing, nervousness, shortness of breath, 
unusual smells and tastes. These surveys were completed by patients under-
going ASCT at the Royal Hobart Hospital, as well as both their carer and 
attending nurse. 
Exploratory analysis of the VASQOL responses for all the symptoms 
previously assoCiated with reinfusion (flushing, nausea, shortness of breath, 
pain, unusual smells and tastes) [Rowley et al., 1999a] suggested that the 
most commonly reported side effect following ASCT for patients was un-
usual tastes although nausea and flushing were also concerns. In addition, 
unusual smells were the most commonly reported ASCT side effect for both 
the carers and nurses. The average VASQOL scores for the Washed and Un-
washed groups suggested all of those individuals (patients, nurses and carers) 
involved with Washed ASCT experienced a faster rate of recovery from these 
ASCT related side effects. 
Analysis of the VASQOL observations was challenging due to a huge 
variability the responses. A possible strategy to reduce variability between 
subjects in future studies could be the use of a fixed set of observers through-
out the VASQOL trial (i.e. nurses). Nevertheless, the data obtained from 
the VASQOL surveys provide an invaluable opportunity for subjective eval-
uation of the symptoms associated with Washed and Unwashed ASCT from 
the perspective of the patients as well as nurses and carers. 
Statistical analysis of the VASQOL responses demonstrated evidence of 
an improvement in the symptoms highlighted by the exploratory analysis 
including flushing, nausea and unpleasant tastes for patients and unusual 
smells for both carers and nurses. It also supported the earlier finding that 
other symptoms, such as shortness of breath and pain, which have been 
associated the ASCT appeared to only be a minor concern for individuals in 
this clinical trial. Therefore, the benefits of the washing protocol to patients 
are two fold. Firstly, from their perspective there is a reduction in the severity 
of several symptoms associated with ASCT which is an improvement on 
current ASCT practise. Secondly, as nursing staff and carers also experience a 
reduction in unpleasant side effects, the ability of these individuals to deliver 
patient care should also be improved. 
The measurement of ASCT patient physical observations pre and post 
reinfusion by nursing staff as part of the clinical trial provided necessary 
insight into the impact of washing HSC on patient well-being. There is 
no significant difference between individuals receiving Washed HSC in com-
parison to Unwashed for patient temperature and urinary haemoglobin. In 
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addition, the data suggests that washing has an significant impact on reduc-
ing the incidence of increased blood pressure associated with ASCT, which 
is an improvement on the current ASCT practise. Furthermore, all of the 
samples from Washed supernatants taken from undamaged cryobags did not 
demonstrate any evidence of bacterial contamination as a consequence of the 
washing protocol. 
The two main strategies for reducing ASCT related toxicity can be divided 
into pre-cryopreservation and post-thawing techniques. As a consequence of 
pre-cryopreservation improvements over time (i.e. refined harvesting, mobil-
ising and processing techniques) the volume of DMSO and cell lysis products 
reinfused into patients have already been reduced [Davis et al., 1990]. A 
previous study of the impact of the NYCBB post-thaw washing procedure 
on ASCT side effects recommended a pre freezing volume reduction and 
hence the amount of DMSO used as a more efficacious approach to reducing 
infusion-related toxicity [Rowley et al., 1999a]. Increasing the NCC during 
cryopreservation to 5 x 108 /ml has accordingly been suggested as a means 
of reducing DMSO requirements [Rowley et al., 1994]. Thus the volumes of 
RSC reinfused into patients continue to be reduced over time and remains a 
primary method of reducing ASCT related toxicity. 
Post-thaw washing of RSC should automatically be considered as a means 
of reducing the increased risks associated with ASCT for patients with heart 
problems such as cardiac amyloid patients [Benekli et al., 2000]. There are 
also a number of other circumstances in which the post-thaw removal of 
DMSO and cellular debris would be useful as in the event of large volume 
reinfusions or patient allergies (e.g. sulphur) by reducing patient exposure 
to the deleterious effects of DMSO [Rubinstein et al., 1995]. Furthermore, 
those patients more likely to experience ASCT related toxicities including 
individuals with easily triggered nausea and vomiting, patients who have been 
heavily conditioned with chemotherapy, or have a smaller body mass ( <70 
kg) would also benefit from the procedure [Synder et al., 2004]. Finally, 
it should also be considered as a option for extending the viability of RSC 
in the event of unexpected delays between thawing and reinfusion of RSC 
[Rubinstein et al., 1995]. 
The post-thaw washing of RSCs presents a number of advantages for the 
those individuals caring for ASCT patients and their ability to deliver patient 
care. Most notably, statistical analysis demonstrated that the working con-
ditions for nurses and carers are improved following the removal of DMSO by 
reducing the unpleasant smell associated with ASCT. A previous study of on-
cology nurses caring for ASCT patients documented that exposure to ASCT 
patients correlated with headaches, nausea, fatigue and patient aversion all 
of which have the potential to affect patient care [Prior et al., 2000]. There-
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fore the removal of DMSO and improvement in working conditions assists 
nurses and carers in their efforts to care and support patients undergoing 
ASCT. Thawing HSCs in the laboratory also provides the opportunity to 
filter platelet clumps before transportation to the ward, therefore removing 
a cause of delay during reinfusion. Additionally, once the HSCs have been 
resuspended post-washing, the time taken by laboratory staff and nursing 
staff to perform the actual reinfusion at the patient bedside is reduced in 
comparison to current ASCT practise. 
The major drawback of the post-thaw HSC washing procedure however 
is the additional time required by laboratory staff to prepare the cells prior 
to reinfusion. Studies of automated cell washing devices to wash cord bloods 
post-thawing have demonstrated that the automation of the NYCBB method 
is safe and suitable [Rodriguez et al., 2004, Perotti et al., 2004]. Therefore 
the use of a automated cell washer may overcome the additional workload 
for laboratory staff and improve the ease of the procedure especially when 
multiple bags are required to be washed while operating in a closed sys-
tem [Lemarie et al., 2005]. Co-ordination between the nurses and laboratory 
staff is also essential prior to the commencement of washing in order to reduce 
delays in reinfusion of HSCs. The adoption of standard operating procedures 
for the reinfusion of washed HSCs (incorporating a time line for communi-
cation between the laboratory and nursing staff prior to the commencement 
of thawing) would improve the delivery washed HSCs to patients. 
Following evaluation of the data collected from the VASQOL surveys, a 
number of improvements could be considered for future trials. The removal 
of symptoms such as nervousness from evaluation by the surveys should be 
contemplated as the data collected was of minimal use and provided no addi-
tional information of the ASCT experience. The impact on laboratory staff 
of the additional work load and responsibility as a result of the post-thaw 
washing procedure could also assessed using QOL surveys and workload study 
tools. Finally, given the time required to gather sufficient data for statistical 
analysis, a multi centre trial using a common protocol could be considered as 
a means to recruit a greater number of subjects within a shorter time period. 
The laboratory validation study demonstrates that this modified NYCBB 
post-thaw washing protocol reduces the amount of DMSO and cellular debris 
reinfused into patients without loss of cell numbers or viability. Furthermore, 
it does not affect the number of CD34+HSCs or their clonogenic potential. 
The findings of the clinical trial indicate that the post-thaw washing im-
proves the quality of life of patients undergoing ASCT and those individuals 
caring for them by reducing the impact of symptoms associated with HSC 
reinfusion. Therefore this method should be recommended as a viable option 
to reduce reinfusion toxicity of cryopreserved HSC. 
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This thesis investigated a washing protocol for use with cryopreserved 
bone marrow and peripheral blood stem cell harvests prior to autologous 
transplantation. The purpose of washing the stem cells is to reduce the tox-
icity associated with the reinfusion of the cryoprotectant dimethyl sulfoxide 
(DMSO), and cellular debris, without compromising the engraftment poten-
tial. Parameters investigated in the laboratory validation included; cell loss, 
overall viability, viable CD34+stem cell enumeration, clonogenic potential 
and reduction in free haemoglobin content. There was no significant loss of 
cell numbers and overall cell viability was improved significantly by DMSO 
removal, a factor that correlated with the decreased incidence of cell clump-
ing. 
Enumeration of viable CD34 +HSC by single platform flow cytometry 
demonstrated that washing did not reduce the number of these crucial cells. 
Similarly, CFU-GM assays demonstrated that washing did not adversely af-
fect HSC clonogenic potential. Washing also removed greater than 903 of 
free haemoglobin (from lysed red blood cells) and, by extrapolation, DMSO 
from harvests. The findings of this study demonstrate that a modified blood 
stem cell washing protocol is a safe laboratory practice with the potential 
to reduce the morbidity associated with the reinfusion of cryopreserved stem 
cells. 
This clinical trial investigated the effect of the washing protocol on HSC 
reinfusion toxicities in comparison to current ASCT practise where cells are 
reinfused without washing immediately after thawing. Nursing observations 
demonstrated that washing had no impact on patient temperature and actu-
ally prevented the rise in systolic blood pressure observed in the Unwashed 
group. Whilst haemoglobinuria is a commonly quoted reinfusion toxicity in 
the literature, this was not frequently observed in our Unwashed cohort, sug-
gesting that modern apheresis techniques have largely ameliorated this side 
effect through reducing the number of red blood cells collected and subse-
quently reinfused. Finally, the possibility of microbiological contamination 
during the washing procedure also appears limited with none observed in this 
study. 
Statistical analysis of the VASQOL responses demonstrated that washing 
resulted in an improvement in several reinfusion toxicity symptoms such as 
flushing, nausea and unpleasant tastes for patients and unusual smells for 
both carers and nurses. This suggests that the washing protocol is not only 
beneficial to patients, but also to nursing staff and carers and subsequently 
may improve their delivery of patient care. 
In conclusion, the laboratory validation of a modified NYCBB protocol 
demonstrates that this procedure does not have any adverse effect on cell 
numbers or viability, CD34+HSC cell counts or clonogenic potential. Basic 
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nursing observations revealed that washing did not have any pyrogenic effect 
upon the patient and prevented reinfusion associated hypertension. The 
clinical trial shows evidence that washing has a significant positive effect 
on the QOL of patients, nurses and carers in comparison to current ASCT 
practice by reducing the impact of a number of reinfusion related symptoms. 
Therefore this washing protocol should be considered for as a alternative to 
the current ASCT method to reduce the side effects associated with ASCT 
without compromising patient care. 
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Chapter 5 
Prospective Investigations 
Whilst this study has demonstrated that washing of thawed HSC products 
has the capacity to reduce the side effects associated with the reinfusion of 
cryopreserved stem cells these findings could be expanded by further inves-
tigations. 
An important consideration prior to the implementation of the washing 
protocol used in this study is the time required by laboratory staff to perform 
the procedure. An evaluation of the impact of the washing protocol on 
the laboratory staff with regard to time taken and work place stress could 
be performed via QOL and work effort surveys, thus providing a complete 
picture of the consequences of the washing protocol of all the individuals 
involved in the ASCT process. Such a study could provide the basis for the 
capital expenditure for an automated cell washer. 
The automation of the washing protocol via the use of automated cell 
washers could further enhance the post-thaw HSC washing procedure. Pre-
vious studies have reported that the manual procedure may take 3 to 4 
hours of work by laboratory staff per patient [Syme et al., 2004]. The pro-
cedure reported in this thesis takes approximately 30 minutes to thaw a 
maximum of two cryobags at a time, hence the post-thaw washing of mul-
tiple bags could be time intensive for laboratory staff. Hence, the use of a 
automated post-thaw washing procedure has been investigated by a num-
ber of researchers. Using NYCBB methodology, a laboratory comparison 
study of 10 manual and 10 automated (using the Sepax 8-100, Biosafe) post-
thaw cord blood washings was conducted. No significant differences were 
observed in CD34+cell numbers and TNC between the two methods. How-
ever, overall processing time was halved and the automated system consid-
erably reducing the required for laboratory staff to wash the HSCs prior to 
reinfusion [Rodriguez et al., 2004]. Therefore, a comparison study of the au-
tomated washing procedure to the manual procedure could investigate both 
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the impact of automation on the time taken to wash HSC as well as scien-
tist workload. Furthermore, a clinical trial could also be conducted using 
VASQOL surveys to assess the consequences of automated HSC washing on 
individuals involved with the reinfusion of HSC in orderto establish if the 
same positive effects as demonstrated in this thesis are observed. 
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